# Patent

## Title
Fused bicyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors

## Abstract

The present invention is directed to novel bicyclic heterocycles of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

## Background
CROSS REFERENCE TO RELATED APPLICATIONS
This application is the National Stage of International Application No. PCT/US2012/027237, filed 1 Mar. 2012, which claims the benefit under 35 U.S.C. 119(e) of U.S. Provisional Application No. 61/448,728, filed 3 Mar. 2011.


FIELD OF THE INVENTION
The present invention relates to fused bicyclic heterocycles which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-4 inhibitors”) and which are useful in the treatment of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
BACKGROUND
Diabetes refers to a disease process derived from multiple causative factors and characterized by elevated levels of plasma glucose or hyperglycemia in the fasting state or after administration of glucose during an oral glucose tolerance test. Persistent or uncontrolled hyperglycemia is associated with increased and premature morbidity and mortality. Often abnormal glucose homeostasis is associated both directly and indirectly with alterations of the lipid, lipoprotein and apolipoprotein metabolism and other metabolic and hemodynamic disease. Therefore patients with Type 2 diabetes mellitus are at especially increased risk of macrovascular and microvascular complications, including coronary heart disease, stroke, peripheral vascular disease, hypertension, nephropathy, neuropathy, and retinopathy. Therefore, therapeutical control of glucose homeostasis, lipid metabolism and hypertension are critically important in the clinical management and treatment of diabetes mellitus.
There are two generally recognized forms of diabetes. In Type 1 diabetes, or insulin-dependent diabetes mellitus (IDDM), patients produce little or no insulin, the hormone which regulates glucose utilization. In Type 2 diabetes, or noninsulin dependent diabetes mellitus (NIDDM), patients often have plasma insulin levels that are the same or even elevated compared to nondiabetic subjects; however, these patients have developed a resistance to the insulin stimulating effect on glucose and lipid metabolism in the main insulin-sensitive tissues, which are muscle, liver and adipose tissues, and the plasma insulin levels, while elevated, are insufficient to overcome the pronounced insulin resistance.
Insulin resistance is not primarily due to a diminished number of insulin receptors but to a post-insulin receptor binding defect that is not yet understood. This resistance to insulin responsiveness results in insufficient insulin activation of glucose uptake, oxidation and storage in muscle and inadequate insulin repression of lipolysis in adipose tissue and of glucose production and secretion in the liver.
The available treatments for Type 2 diabetes, which have not changed substantially in many years, have recognized limitations. While physical exercise and reductions in dietary intake of calories will dramatically improve the diabetic condition, compliance with this treatment is very poor because of well-entrenched sedentary lifestyles and excess food consumption, especially of foods containing high amounts of saturated fat. Increasing the plasma level of insulin by administration of sulfonylureas (e.g. tolbutamide and glipizide) or meglitinide, which stimulate the pancreatic β cells to secrete more insulin, and/or by injection of insulin when sulfonylureas or meglitinide become ineffective, can result in insulin concentrations high enough to stimulate the very insulin-resistant tissues. However, dangerously low levels of plasma glucose can result from administration of insulin or insulin secretagogues (sulfonylureas or meglitinide), and an increased level of insulin resistance due to the even higher plasma insulin levels can occur. The biguanides increase insulin sensitivity resulting in some correction of hyperglycemia. However, the two biguanides, phenformin and metformin, can induce lactic acidosis and nausea/diarrhea. Metformin has fewer side effects than phenformin and is often prescribed for the treatment of Type 2 diabetes.
The glitazones (i.e. 5-benzylthiazolidine-2,4-diones) constitute an additional class of compounds with potential for ameliorating many symptoms of Type 2 diabetes. These agents substantially increase insulin sensitivity in muscle, liver and adipose tissue in several animal models of Type 2 diabetes resulting in partial or complete correction of the elevated plasma levels of glucose without occurrence of hypoglycemia. The glitazones that are currently marketed are agonists of the peroxisome proliferator activated receptor (PPAR), primarily the PPAR-gamma subtype. PPAR-gamma agonism is generally believed to be responsible for the improved insulin sensitization that is observed with the glitazones. Newer PPAR agonists that are being tested for treatment of Type 2 diabetes are agonists of the alpha, gamma or delta subtype, or a combination of these, and in many cases are chemically different from the glitazones (i.e., they are not thiazolidinediones in structure). Serious side effects (e.g. liver toxicity) have occurred with some of the glitazones, such as troglitazone.
Additional methods of treating the disease are still under investigation. New biochemical approaches that have been recently introduced or are still under development include alpha-glucosidase inhibitors (e.g. acarbose), GLP-1 mimetics (e.g., exenatide and liraglutide), glucagon receptor antagonists, glucokinase activators, and GPR-119 agonists.
Compounds that are inhibitors of the dipeptidyl peptidase-IV (“DPP-4”) enzyme have also been found useful for the treatment of diabetes, particularly Type 2 diabetes [See WO 97/40832; WO 98/19998; U.S. Pat. No. 5,939,560; U.S. Pat. No. 6,303,661; U.S. Pat. No. 6,699,871; U.S. Pat. No. 6,166,063; Bioorg. Med. Chem. Lett., 6: 1163-1166 (1996); Bioorg. Med. Chem. Lett. 6: 2745-2748 (1996); D. J. Drucker in Exp. Opin. Invest. Drugs, 12: 87-100 (2003); K. Augustyns, et al., Exp. Opin. Ther. Patents, 13: 499-510 (2003); Ann E. Weber, J. Med. Chem., 47: 4135-4141 (2004); J. J. Holst, Exp. Opin. Emer. Drugs, 9: 155-166 (2004); D. Kim, et al., J. Med. Chem., 48: 141-151 (2005); K. Augustyns, Exp. Opin. Ther. Patents, 15: 1387-1407 (2005); H.-U. Demuth in Biochim. Biophys. Acta, 1751: 33-44 (2005); and R. Mentlein, Exp. Opin. Invest. Drugs, 14: 57-64 (2005).
Additional patent publications that disclose DPP-4 inhibitors useful for the treatment of diabetes are the following: WO 2006/009886 (26 Jan. 2006); WO 2006/039325 (13 Apr. 2006); WO 2006/058064 (1 Jun. 2006); WO 2006/127530 (30 Nov. 2006); WO 2007/024993 (1 Mar. 2007); WO 2007/070434 (21 Jun. 2007); WO 2007/087231 (2 Aug. 2007); WO 07/097,931 (30 Aug. 2007); WO 07/126,745 (8 Nov. 2007); WO 07/136,603 (29 Nov. 2007); and WO 08/060,488 (22 May 2008).
The usefulness of DPP-4 inhibitors in the treatment of Type 2 diabetes is based on the fact that DPP-4 in vivo readily inactivates glucagon like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). GLP-1 and GIP are incretins and are produced when food is consumed. The incretins stimulate production of insulin. Inhibition of DPP-4 leads to decreased inactivation of the incretins, and this in turn results in increased effectiveness of the incretins in stimulating production of insulin by the pancreas. DPP-4 inhibition therefore results in an increased level of serum insulin. Advantageously, since the incretins are produced by the body only when food is consumed, DPP-4 inhibition is not expected to increase the level of insulin at inappropriate times, such as between meals, which can lead to excessively low blood sugar (hypoglycemia). Inhibition of DPP-4 is therefore expected to increase insulin without increasing the risk of hypoglycemia, which is a dangerous side effect associated with the use of insulin secretagogues.
DPP-4 inhibitors also have other therapeutic utilities, as discussed herein. New compounds are needed so that improved DPP-4 inhibitors can be found for the treatment of diabetes and potentially other diseases and conditions. In particular, there is a need for DPP-4 inhibitors that are selective over other members of the family of serine peptidases that includes quiescent cell proline dipeptidase (QPP), DPP8, and DPP9 [see G. Lankas, et al., “Dipeptidyl Peptidase-IV Inhibition for the Treatment of Type 2 Diabetes: Potential Importance of Selectivity Over Dipeptidyl Peptidases 8 and 9,” Diabetes, 54: 2988-2994 (2005); N. S. Kang, et al., “Docking-based 3D-QSAR study for selectivity of DPP4, DPP8, and DPP9 inhibitors,” Bioorg. Med. Chem. Lett., 17: 3716-3721 (2007)].
The therapeutic potential of DPP-4 inhibitors for the treatment of Type 2 diabetes is discussed by (i) D. J. Drucker, Exp. Opin. Invest. Drugs, 12: 87-100 (2003); (ii) K. Augustyns, et al., Exp. Opin. Ther. Patents, 13: 499-510 (2003); (iii) J. J. Hoist, Exp. Opin. Emerg. Drugs, 9: 155-166 (2004); (iv) H.-U. Demuth, et al., Biochim. Biophys. Acta, 1751: 33-44 (2005); (v) R. Mentlein, Exp. Opin. Invest. Drugs, 14: 57-64 (2005); (vi) K. Augustyns, “Inhibitors of proline-specific dipeptidyl peptidases: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetes,” Exp. Opin. Ther. Patents, 15: 1387-1407 (2005); (vii) D. J. Drucker and M. A. Nauck, “The incretin system: GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in Type 2 diabetes,” The Lancet, 368: 1696-1705 (2006); (viii) T. W. von Geldern and J. M. Trevillyan, ““The Next Big Thing” in Diabetes: Clinical Progress on DPP-IV Inhibitors,” Drug Dev. Res., 67: 627-642 (2006); (ix) B. D. Green et al., “Inhibition of dipeptidyl peptidase IV activity as a therapy of Type 2 diabetes,” Exp. Opin. Emerging Drugs, 11: 525-539 (2006); (x) J. J. Hoist and C. F. Deacon, “New Horizons in Diabetes Therapy,” Immun., Endoc. & Metab. Agents in Med. Chem., 7: 49-55 (2007); (xi) R. K. Campbell, “Rationale for Dipeptidyl Peptidase 4 Inhibitors: a New Class of Oral Agents for the Treatment of Type 2 Diabetes Mellitus,” Ann. Pharmacother., 41: 51-60 (2007); (xii) Z. Pei, “From the bench to the bedside: Dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents,” Curr. Opin. Drug Discovery Development, 11: 512-532 (2008); and (xiii) J. J. Hoist, et al., “Glucagon-like peptide-1, glucose homeostasis, and diabetes, Trends in Molecular Medicine, 14: 161-168 (2008). Specific DPP-4 inhibitors either already approved or under clinical investigation for the treatment of Type 2 diabetes include sitagliptin, vildagliptin, saxagliptin, alogliptin, carmegliptin, melogliptin, and dutogliptin.
SUMMARY OF THE INVENTION
Described herein are dipeptidyl peptidase-IV enzyme inhibitors (“DPP-4 inhibitors”) of formula I:




wherein X1, X2, n, R1, R2 and R5 are described herein.

Also described herein are fused bicyclic heterocyclic compounds of the formulas described herein which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-4 inhibitors”) and which are useful in the treatment of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.


DETAILED DESCRIPTION OF THE INVENTION
Compounds
A compound of structural formula I:




or a pharmaceutically acceptable salts thereof; wherein X1 and X2 are independently selected from the group consisting of —N— and —CR5—;

R1 is selected from the group consisting of hydrogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, aryl, heterocycle, aroyl, heteroaroyl and C3-C10cycloalkyl; wherein the C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, aryl, heterocycle, aroyl, heteroaroyl and C3-C10cycloalkyl are unsubstituted or substituted with 1-3 substituents from R5;
R2 is selected from the group consisting of C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, benzyl, heterocycle and C1-C6alkylheterocycle; wherein the C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, benzyl, heterocycle and C1-C6alkylheterocycle are unsubstituted or substituted with 1-3 substituents each independently selected from R3, R4 and R5;
R3 is selected from the group consisting of hydrogen, C1-C6alkyl and aryl, wherein the C1-C6alkyl and aryl are unsubstituted or substituted with 1-3 substituents selected from R5;
R4 is selected from the group consisting of hydrogen and C1-C6alkyl;
R5 is selected from the group consisting of hydrogen, halogen, C1-C6alkyl, halogen-substitutedC1-C6alkyl, —OH, C1-C6alkylOH, halogen-substitutedC1-C6alkylOH, —OC1-C6alkyl, —Ohalogen-substitutedC1-C6alkyl, —COOH, —COOC1-C6alkyl, —C1-C6alkylCOOC1-C6alkyl, —C1-C6alkylCOOH, —CN, C1-C6alkylCN, NHC1-C6alkyl, N(C1-C6alkyl)2, C1-C6alkylCONH2, —CONH2, —CONHC1-C6alkyl, —NHCOC1-C6alkyl, —CON(C1-C6alkyl)2, —NHSO2C1-C6alkyl, SO2aryl, —SO2C1-C6alkyl, C1-C6alkylSO2C1-C6alkyl, aryl, —NHCOaryl, and —NHCOheterocycle; and
n is 0-4.
With regard to the compounds described herein, X1 and X2 are independently selected from the group consisting of —N— and —CR5—. In certain embodiments of the compounds described herein, X1 is selected from the group consisting of —N— and —CR5—. In other embodiments, X1 is —N—. In other embodiments, X1 is —CR5—. In yet other embodiments of the compounds described herein, X2 is selected from the group consisting of —N— and —CR5—. In other embodiments, X2 is —N—. In still other embodiments, X2 is —CR5—.
For example, in some of the embodiments of the compounds described herein, X1 is —N— and X2 is —CR5—. In other embodiments of the compounds described herein, X1 and X2 are —N—.
In the embodiments described herein wherein X1 or X2 are —CR5—, R5 is further described below. In certain embodiments R5 is selected from the group consisting of hydrogen and halogen. In one embodiment, R5 is hydrogen. In another embodiment R5 is halogen. Suitable halogens include, but are not limited to, chlorine and fluorine.
With regard to the compounds described herein, n is 0-4. In certain embodiments of the compounds described herein, n is 0. In certain embodiments of the compounds described herein, n is 1. In other embodiments, n is 2. In another embodiment, n is 3. In yet another embodiment, n is 4. In still another embodiment, n is 1-3. In another embodiment, n is 1-2.
With regard to the compounds described herein, R1 is selected from the group consisting of hydrogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, aryl, heterocycle, aroyl, heteroaroyl and C3-C10cycloalkyl; wherein the C1-C6alkyl, C2-C6alkenyl and C2-C6alkynyl, aryl, heterocycle, aroyl, heteroaroyl and C3-C10cycloalkyl are unsubstituted or substituted with 1-3 substituents from R5.
In certain embodiments of the compounds described herein, R1 is hydrogen.
In certain embodiments of the compounds described herein, R1 is C1-C6alkyl. Suitable C1-C6alkyls include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl and 1-ethyl-1-methylpropyl.
In certain embodiments of the compounds described herein, R1 is C2-C6alkenyl. Suitable C2-C6alkenyls include ethenyl, propenyl, n-butenyl, 3-methylbut-2-enyl and n-pentenyl.
In certain embodiments of the compounds described herein, R1 is C2-C6alkynyl. Suitable C2-C6alkynyls include ethynyl, propynyl, 2-butynyl and 3-methylbutynyl.
In certain embodiments, R1 is aryl. Suitable aryls include phenyl and naphthyl.
In certain embodiments, R1 is heterocycle. Suitable heterocycles include any nitrogen-containing mono or bicyclic rings. In certain embodiments, R1 is a nitrogen-containing bicyclic group. Examples include, but are not limited to,







In still other embodiments of the compounds described herein, R1 is aroyl. Suitable aroyls include benzoyl and napthoyl.
In yet other embodiments of the compounds described herein, R1 is heteroaroyl. Suitable heteroaroyls include furoyl, nictinoyl and iso-nicotinoyl.
In other embodiments of the compounds described herein, R1 is C3-C10cycloalkyl. Suitable C3-C10cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohepta-1,3-dienyl and cyclooctyl.
In one embodiment, R1 is selected from the group consisting of:










In one embodiment R1 is selected from the group consisting of:




In another embodiment, R1 is




wherein R5 is C1-C6alkyl. Suitable C1-C6alkyls include methyl, ethyl, propyl and butyl. In one embodiment, R5 is methyl.
In certain embodiments of the compounds described herein, R1 is unsubstituted. In other embodiments of the compounds described herein R1 is substituted with 1-3 substituents independently selected from R5. In one embodiment of the compounds described herein R1 is substituted with 1 substituent selected from R5. In another embodiment of the compounds described herein R1 is substituted with 2 substituents independently selected from R5. In still yet another embodiment of the compounds described herein R1 is substituted with 3 substituents independently selected from R5.
With regard to the compounds described herein, R2 is selected from the group consisting of C2-C6alkenyl, C2-C6alkynyl, benzyl, heterocycle and C1-C6alkylheterocycle; wherein the C2-C6alkenyl, C2-C6alkynyl, benzyl, heterocycle and C1-C6alkylheterocycle are unsubstituted or substituted with 1-3 substituents each independently selected from R3, R4 and R5. In certain embodiments, R2 is C2-C6alkenyl. Suitable C2-C6alkenyls include ethenyl, propenyl, n-butenyl, 3-methylbut-2-enyl and n-pentenyl. In other embodiments, R2 is C2-C6alkynyl. Suitable C2-C6alkynyls include ethynyl, propynyl, 2-propynyl, 2-butynyl and 3-methylbutynyl. For example in some embodiments, R2 is 2-butynyl. In one embodiment, R2 is benzyl.
In still other embodiments of the compounds described herein, R2 is selected from the group consisting of heterocycle and C1-C6alkylheterocycle.
In certain embodiments, R2 is unsubstituted. In another embodiment, R2 is substituted with 1-3 substituents from selected from R3. In still another embodiment, R2 is substituted with 1-3 substituents from selected from R4. In yet another embodiment, R2 is substituted with 1-3 substituents from selected from R5. In certain embodiments, R2 is substituted with 1-3 substituents from selected from R3 and R4. In other embodiments, embodiments, R2 is substituted one substituent selected from R3 and one substituent selected from R4.
In one embodiment R2 is substituted with 1 substituent selected from R5. In one embodiment R2 is substituted with 2 substituents selected from R5. In one embodiment R2 is substituted with 3 substituents selected from R5. In another embodiment, R2 is benzyl, wherein the benzyl is unsubstituted or substituted with 1-3 substituents each independently selected from R5. In another embodiment, R2 is a heterocycle, wherein the heterocycle is unsubstituted or substituted with 1-3 substituents each independently selected from R5.
In certain embodiments of the compounds described herein, R2 is selected from the group consisting of:







In another embodiment, R2 is selected from the group consisting of C2-C6alkenyl, C2-C6alkynyl and benzyl, wherein C2-C6alkenyl, C2-C6alkynyl and benzyl are unsubstituted or substituted with 1-3 substituents selected from R5. In yet another embodiment, R2 is selected from the group consisting of 2-butynyl, 2,5-difluorobenzyl, 2,4,5-trifluorobenzyl, 2-cyanobenzyl, 2-cyano-5-fluorobenzyl, 2-cyano-4,5-difluorobenzyl, 2,4-dichlorobenzyl, 2,5-dichlorobenzyl and 2-bromo-5-fluorobenzyl.
In yet another embodiment, R2 is benzyl, wherein the benzyl is unsubstituted or substituted with 1-3 substituents selected from the group R5. For example, R2 is benzyl, wherein the benzyl is substituted with one or two substituents independently selected from fluoro and —CN.
With regard to the compounds described herein, R3 is selected from the group consisting of hydrogen, C1-C6alkyl and aryl, wherein the aryl is unsubstituted or substituted with 1-3 substituents selected from R5. In certain embodiments of the compounds described herein, R3 is hydrogen. In other embodiments of the compounds described herein, R3 is C1-C6alkyl, Suitable C1-C6alkyls include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl and 1-ethyl-1-methylpropyl. In yet another embodiment, R3 is aryl. Suitable aryls include phenyl and napthyl.
In one embodiment R3 is aryl wherein the aryl is unsubstituted. In another embodiment R3 is aryl, wherein the aryl is substituted with 1 substituent selected from R5. In one embodiment R3 is aryl, wherein the aryl is substituted with 2 substituents selected from R5. In one embodiment R3 is aryl, wherein the aryl is substituted with 3 substituents selected from R5.
With regard to the compounds described herein, R4 is selected from the group consisting of hydrogen and C1-C6alkyl. In certain embodiments of the compounds described herein, R4 is hydrogen. In other embodiments of the compounds described herein, R4 is C1-C6alkyl. Suitable C1-C6alkyls include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl and 1-ethyl-1-methylpropyl.
In certain embodiments of the compounds described herein, R5 is selected from the group consisting of hydrogen, halogen, C1-C6alkyl, halogen-substitutedC1-C6alkyl, —OH, C1-C6alkylOH, halogen-substitutedC1-C6alkylOH, —OC1-C6alkyl, —Ohalogen-substitutedC1-C6alkyl, —COOH, —COOC1-C6alkyl, —C1-C6alkylCOOC1-C6alkyl, —C1-C6alkylCOOH, —CN, C1-C6alkylCN, NHC1-C6alkyl, N(C1-C6alkyl)2, C1-C6alkylCONH2, —CONH2, —CONHC1-C6alkyl, —NHCOC1-C6alkyl, —CON(C1-C6alkyl)2, —NHSO2C1-C6alkyl, SO2aryl, —SO2C1-C6alkyl, C1-C6alkylSO2C1-C6alkyl, aryl, —NHCOaryl, and —NHCOheterocycle.
For example, in one embodiment R5 is hydrogen. In another embodiment, R5 is halogen. Suitable halogens include chlorine, fluorine, bromine and iodine. In yet another embodiment, R5 is C1-C6alkyl. Suitable C1-C6alkyls include methyl, ethyl, propyl and butyl. In yet another embodiment, R5 is halogen-substitutedC1-C6alkyl. Suitable halogen-substitutedC1-C6alkyls include fluoromethyl, difluorormethyl and trifluoromethyl. In still another embodiment, R5 is —OH, C1-C6alkylOH or halogen-substitutedC1-C6alkylOH. In another embodiment, R5 is —OC1-C6alkyl and —Ohalogen-substitutedC1-C6alkyl. Suitable examples include methoxy and trifluoromethoxy.
In still other embodiments of the compounds described herein, R5 is —COOH, —COOC1-C6alkyl, —C1-C6alkylCOOC1-C6alkyl, —C1-C6alkylCOOH or —OC1-C6alkylCOOH. In another embodiment, R5 is —CN. In yet another embodiment, R5 is C1-C6alkylCN. In other embodiments, R5 is NHC1-C6alkyl or N(C1-C6alkyl)2. In yet other embodiments, R5 is C1-C6alkylCONH2, —CONH2, —CONHC1-C6alkyl, —NHCOC1-C6alkyl or —CON(C1-C6alkyl)2. In another embodiment, R5 is NHSO2C1-C6alkyl, SO2aryl, wherein the aryl is phenyl or napthyl, C1-C6alkylSO2C1-C6alkyl or —SO2C1-C6alkyl.
In certain embodiments of the compounds described herein, R5 is aryl, wherein the aryl is phenyl or napthyl. In other embodiments, R5 is —NHCOaryl or —NHCOheterocycle, wherein the aryl is phenyl or napthyl and the heterocycle is pyrrolyl, thienyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, indolyl, benzothienyl, benzimidazolyl, benzopyrazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, indazolyl.
In certain embodiments of the compounds described herein, R5 is selected from the group consisting of halogen and —CN.
Also described herein are compounds of structural formula Ia:




or a pharmaceutically acceptable salts thereof; wherein X1, X2, n, R1, R2 and R5 are described as above.

In one embodiment of the compounds of formula Ia, X1 is —N— and X2 is selected from the group consisting of —N— and —CR5—; n is 1, R1 is hydrogen and R2 is benzyl wherein the benzyl is unsubstituted or substituted with 1-3 substitutents selected from the group consisting of halogen and —CN.
Also described herein are compounds of structural formulas II and III:




or a pharmaceutically acceptable salts thereof; wherein R1 and R2 are described as above.

Embodiments of the compounds described herein include, but are not limited to:







DEFINITIONS
As used herein the following definitions are applicable.
Examples of “halogen” include a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
The term “C1-C6alkyl” encompasses straight alkyl having a carbon number of 1 to 6 and branched alkyl having a carbon number of 3 to 6. Specific examples thereof include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-2-methylpropyl, 1-ethyl-1-methylpropyl, and the like.
The term “halogen-substitutedC1-C6 alkyl” encompasses C1-C6 alkyl with the hydrogen atoms thereof being partially or completely substituted with halogen, examples thereof including fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, 2,2-difluoroethyl and the like.
The term “C2-C6alkenyl” as used herein, refers to an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and may be straight or branched and contains from about 2 to about 6 carbon atoms. Non-limiting examples of alkenyl groups include ethenyl, propenyl, n-butenyl, 3-methylbut-2-enyl and n-pentenyl.
The term “C2-C6alkynyl,” as used herein, refers to an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond and which may be straight or branched and contains from about 2 to about 6 carbon atoms. In one embodiment, an alkynyl group contains from about 2 to about 12 carbon atoms. In another embodiment, an alkynyl group contains from about 2 to about 6 carbon atoms. Non-limiting examples of alkynyl groups include ethynyl, propynyl, 2-butynyl and 3-methylbutynyl.
The term “aryl,” as used herein, refers to an aromatic monocyclic or multicyclic ring system comprising from about 6 to about 14 carbon atoms. In one embodiment, an aryl group contains from about 6 to about 10 carbon atoms. An aryl group can be optionally substituted with one or more “ring system substituents” which may be the same or different, and are as defined herein below. Non-limiting examples of aryl groups include phenyl and naphthyl. In one embodiment, an aryl group is unsubstituted. In another embodiment, an aryl group is phenyl.
The term “C3-C10cycloalkyl,” as used herein, refers to a monocyclic or polycyclic, saturated cycloalkyls having from 3 to 10 carbon atoms. Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl and cyclooctyl. Non-limiting examples of multicyclic cycloalkyls include 1-decalinyl, norbornyl and adamantyl. In one embodiment, a cycloalkyl group is unsubstituted.
The term “aroyl” refers to the radical RCO, where R is an aromatic ring. Examples include benzoyl and napthoyl.
The term “heteroaroyl” refers to the radical RCO, where R is a hetero-aromatic ring. Examples include, but are not limited to, furoyl, nicbtinoyl and iso-nicotinoyl.
The term “—OC1-C6alkyl” refers to an alkyl group having 1 to 6 carbons linked to oxygen, also known as an alkoxy group. Examples include methoxy, ethoxy, butoxy and propoxy.
The term “—Ohalogen-substitutedC1-C6alkyl” means a —OC1-C6alkyl as defined above, which is substituted with 1-3 halogen atoms which are identical or different, and specifically includes, for example, a trifluoromethoxy group.
The term “C1-C6alkylOH” means a C1-C6alkyl substituted with an alcohol (—OH). Examples include methanol, propanol, butanol and t-butanol.
The term “halogen-substituted C1-C6alkylOH” means a halogen-substituedC1-C6alkyl substituted with an alcohol (—OH).
The term “COOC1-C6alkyl” means a —COOH group wherein the —OH is replaced with an alkoxy group as defined above. Examples include methoxycarbonyl, ethoxycarbonyl and butoxycarbonyl.
The term “C1-C6alkylCOOH” means a C1-C6alkyl substituted with a caboxcylic acid (COOH).
The term “OC1-C6alkylCOOH” means alkoxy substituted with a caboxcylic acid (COOH).
The term “C1-C6alkylCN” means a C1-C6alkyl substituted with a cyano group (—CN).
The term “NHC1-C6alkyl” means a group with one of the hydrogen atoms of amino (—NH2) being substituted with a C1-6alkyl group. Specific examples thereof include methylamino, ethylamino, n-propylamino, isopropylamino, n-butylamino, sec-butylamino, tert-butylamino, and the like.
The term “N(C1-C6alkyl)2” means a group with the two amino hydrogen atoms each being substituted with a C1-6alkyl group. Specific examples thereof include dimethylamino, diethylamino, ethylmethylamino, di(n-propyl)amino, methyl(n-propyl)amino, diisopropylamino, and the like.
The term “SO2C1-C6alkyl” means a group having C1-C6alkyl bonded to sulfonyl (—SO2—). Specific examples thereof include methanesulfonyl, ethanesulfonyl, n-propanesulfonyl, isopropanesulfonyl, n-butanesulfonyl, sec-butanesulfonyl, tert-butanesulfonyl, and the like.
The term “CONHC1-C6alkyl” means a group with one of the hydrogen atoms of carbamoyl (—CONH2) being substituted with C1-6alkyl. Specific examples thereof include methylcarbamoyl, ethylcarbamoyl, n-propylcarbamoyl, isopropylcarbamoyl, n-butylcarbamoyl, sec-butylcarbamoyl, tert-butylcarbamoyl, and the like.
The term “CON(C1-C6alkyl)2” means a group with the two carbamoyl hydrogen atoms each being substituted with C1-6alkyl. Specific examples thereof include dimethylcarbamoyl, diethylcarbamoyl, ethylmethylcarbamoyl, di(n-propyl)carbamoyl, methyl(n-propyl)carbamoyl, diisopropylcarbamoyl, and the like.
The term “NHSO2C1-C6alkyl” means a group with one of the amino hydrogen atoms being substituted with C1-6alkylsulfonyl. Specific examples thereof include methanesulfonylamino, ethanesulfonylamino, n-propanesulfonylamino, isopropanesulfonylamino, n-butanesulfonylamino, sec-butanesulfonylamino, tert-butanesulfonylamino, and the like.
The term “NHCOC1-C6alkyl” means a group with one of the amino hydrogen atoms being substituted with C1-6alkylcarbonyl and encompasses alkylcarbonylamino having a carbon number of 1 to 6. Specific examples thereof include methylcarbonylamino, ethylcarbonylamino, n-propylcarbonylamino, isopropylcarbonylamino, n-butylcarbonylamino, isobutylcarbonylamino, tert-butylcarbonylamino, n-pentylcarbonylamino, and the like.
The term “heterocycle” means a saturated, partially-unsaturated or aromatic mono or multicyclic ring containing one or more, preferably one to three, same or different heteroatoms preferably selected from the group consisting of a nitrogen atom, and a sulfur atom. Examples thereof include pyrrolyl, pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, pyridone (including N-substituted pyridones), isoxazolyl, isothiazolyl, oxazolyl, oxadiazolyl, 1,3,4-thiadiazolyl, isoxazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, pyridazinyl, quinoxalinyl, phthalazinyl, oxindolyl, imidazo[1,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolinyl, imidazolyl, thienopyridyl, quinazolinyl, thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, isoquinolinyl, benzoazaindolyl, 1,2,4-triazinyl, 1,3,5-triazinyl, indolyl, benzothiazolyl, benzopyrazolyl, benzoxazolyl, benzisoxazolyl, benzisothiazolyl, indazolyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, piperazinyl, dioxanyl, imidazolidinyl, 2,3-dihydrofuro(2,3-b)pyridyl, benzoxazinyl, benzoxazolinyl, dihydrophthalazinyl, isoindolinyl, benzoxazepinyl, 5,6-dihydroimidazo[2,1-b]thiazolyl, tetrahydroquinolinyl, morpholinyl, tetrahydroisoquinolinyl, dihydroindolyl, thiomorpholinyl, thiazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, lactam, lactone, 1,2,3,4-tetrahydropyridinyl, 1,2-dihydropyridinyl, 1,4-dihydropyridinyl, 1,2,3,6-tetrahydropyridinyl, 1,4,5,6-tetrahydropyrimidinyl, 2-pyrrolinyl, 3-pyrrolinyl, 2-imidazolinyl, 2-pyrazolinyl, dihydroimidazolyl, dihydrooxazolyl, dihydrooxadiazolyl, dihydrothiazolyl, 3,4-dihydro-2H-pyranyl, dihydrofuranyl, fluoro-substituted dihydrofuranyl, 7-oxabicyclo[2.2.1]heptenyl, dihydrothiophenyl, dihydrothiopyranyl, and the like. The term also includes partially unsaturated monocyclic rings that are not aromatic, such as 2- or 4-pyridones attached through the nitrogen or N-substituted-(1H,3H)-pyrimidine-2,4-diones (N-substituted uracils). The term also includes bridged rings such as 5-azabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.1]heptyl, 2-azabicyclo[2.2.1]heptyl, 7-azabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.2]octyl, 2-azabicyclo[2.2.2]octyl, and 3-azabicyclo[3.2.2]nonyl, and azabicyclo[2.2.1]heptanyl.
The compounds of the present invention contain one or more asymmetric centers and can thus occur as racemates, racemic mixtures, single enantiomers, diastereomeric mixtures, and individual diastereomers. Each such asymmetric center will independently produce two optical isomers and it is intended that all of the possible optical isomers and diastereomers in mixtures and as pure or partially purified compounds are included within the ambit of this invention. The present invention is meant to comprehend all such isomeric forms of these compounds.
Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.
Some of the compounds described herein may exist as tautomers, which have different points of attachment of hydrogen accompanied by one or more double bond shifts. For example, a ketone and its enol form are keto-enol tautomers. The individual tautomers as well as mixtures thereof are encompassed with compounds of the present invention.
The independent syntheses of these diastereomers or their chromatographic separations may be achieved as known in the art by appropriate modification of the methodology disclosed herein. Their absolute stereochemistry may be determined by the X-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration.
If desired, racemic mixtures of the compounds may be separated so that the individual enantiomers are isolated. The separation can be carried out by methods well known in the art, such as the coupling of a racemic mixture of compounds to an enantiomerically pure compound to form a diastereomeric mixture, followed by separation of the individual diastereomers by standard methods, such as fractional crystallization or chromatography. The coupling reaction is often the formation of salts using an enantiomerically pure acid or base. The diasteromeric derivatives may then be converted to the pure enantiomers by cleavage of the added chiral residue. The racemic mixture of the compounds can also be separated directly by chromatographic methods utilizing chiral stationary phases, which methods are well known in the art.
Alternatively, any enantiomer of a compound may be obtained by stereoselective synthesis using optically pure starting materials or reagents of known configuration by methods well known in the art.
In the compounds of generic Formula I, Ia, II or III, the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present invention is meant to include all suitable isotopic variations of the compounds of generic Formula I, Ia, II or III. For example, different isotopic forms of hydrogen (H) include protium (1H) and deuterium (2H). Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples. Isotopically-enriched compounds within generic Formula I, Ia, II or III can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.
It will be understood that, as used herein, references to the compounds of structural Formula I, Ia, II or III are meant to also include the pharmaceutically acceptable salts, and also salts that are not pharmaceutically acceptable when they are used as precursors to the free compounds or their pharmaceutically acceptable salts or in other synthetic manipulations.
The compounds of the present invention may be administered in the form of a pharmaceutically acceptable salt. The term “pharmaceutically acceptable salt” refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. Salts of basic compounds encompassed within the term “pharmaceutically acceptable salt” refer to non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid. Representative salts of basic compounds of the present invention include, but are not limited to, acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, camsylate, carbonate, clavulanate, citrate, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, oleate, oxalate, pamoate (embonate), palmitate, pantothenate, phosphate, polygalacturonate, salicylate, stearate, sulfate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide and valerate. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof include, but are not limited to, salts derived from inorganic bases including aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, mangamous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, cyclic amines, and basic ion-exchange resins, such as arginine, betaine, caffeine, choline, N,N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
Also, in the case of a carboxylic acid (—COOH) or alcohol group being present in the compounds of the present invention, pharmaceutically acceptable esters of carboxylic acid derivatives, such as methyl, ethyl, or pivaloyloxymethyl, or acyl derivatives of alcohols, such as O-acetyl, O-pivaloyl, O-benzoyl, and O-aminoacyl, can be employed. Included are those esters and acyl groups known in the art for modifying the solubility or hydrolysis characteristics for use as sustained-release or prodrug formulations.
Solvates, and in particular, the hydrates of the compounds of structural Formula I, Ia, II or III are included in the present invention as well.
Methods of Treatment
The subject compounds are useful in a method of inhibiting the dipeptidyl peptidase-IV enzyme in a patient such as a mammal in need of such inhibition comprising the administration of an effective amount of the compound. The present invention is directed to the use of the compounds disclosed herein as inhibitors of dipeptidyl peptidase-IV enzyme activity.
In addition to primates, such as humans, a variety of other mammals can be treated according to the method of the present invention. For instance, mammals including, but not limited to, cows, sheep, goats, horses, dogs, cats, guinea pigs, rats or other bovine, ovine, equine, canine, feline, rodent or murine species can be treated. However, the method can also be practiced in other species, such as avian species (e.g., chickens).
The present invention is further directed to a method for the manufacture of a medicament for inhibiting dipeptidyl peptidase-IV enzyme activity in humans and animals comprising combining a compound of the present invention with a pharmaceutically acceptable carrier or diluent. More particularly, the present invention is directed to the use of a compound of structural Formula I, Ia, II or III in the manufacture of a medicament for use in treating a condition selected from the group consisting of hyperglycemia, Type 2 diabetes, obesity, and a lipid disorder in a mammal, wherein the lipid disorder is selected from the group consisting of dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL, and high LDL.
The subject treated in the present methods is generally a mammal, preferably a human being, male or female, in whom inhibition of dipeptidyl peptidase-IV enzyme activity is desired. The term “therapeutically effective amount” means the amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.
The term “composition” as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. Such term in relation to pharmaceutical composition, is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier. By “pharmaceutically acceptable” it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
The terms “administration of” and or “administering a” compound should be understood to mean providing a compound of the invention or a prodrug of a compound of the invention to the individual in need of treatment.
Dipeptidyl peptidase-IV enzyme (DPP-4) is a cell surface protein that has been implicated in a wide range of biological functions. It has a broad tissue distribution (intestine, kidney, liver, pancreas, placenta, thymus, spleen, epithelial cells, vascular endothelium, lymphoid and myeloid cells, serum), and distinct tissue and cell-type expression levels. DPP-4 is identical to the T cell activation marker CD26, and it can cleave a number of immunoregulatory, endocrine, and neurological peptides in vitro. This has suggested a potential role for this peptidase in a variety of disease processes in humans or other species.
Accordingly, the subject compounds are useful in a method for the prevention or treatment of the following diseases, disorders and conditions:
Type II Diabetes and Related Disorders
It is well established that the incretins GLP-1 and GIP are rapidly inactivated in vivo by DPP-4. Studies with DPP-4(−/−)-deficient mice and preliminary clinical trials indicate that DPP-4 inhibition increases the steady state concentrations of GLP-1 and GIP, resulting in improved glucose tolerance. By analogy to GLP-1 and GIP, it is likely that other glucagon family peptides involved in glucose regulation are also inactivated by DPP-4 (eg. PACAP). Inactivation of these peptides by DPP-4 may also play a role in glucose homeostasis. The DPP-4 inhibitors of the present invention therefore have utility in the treatment of type II diabetes and in the treatment and prevention of the numerous conditions that often accompany Type II diabetes, including Syndrome X (also known as Metabolic Syndrome), reactive hypoglycemia, and diabetic dyslipidemia. Obesity, discussed below, is another condition that is often found with Type II diabetes that may respond to treatment with the compounds of this invention.
The following diseases, disorders and conditions are related to Type 2 diabetes, and therefore may be treated, controlled or in some cases prevented, by treatment with the compounds of this invention: (1) hyperglycemia, (2) low glucose tolerance, (3) insulin resistance, (4) obesity, (5) lipid disorders, (6) dyslipidemia, (7) hyperlipidemia, (8) hypertriglyceridemia, (9) hypercholesterolemia, (10) low HDL levels, (11) high LDL levels, (12) atherosclerosis and its sequalae, (13) vascular restenosis, (14) irritable bowel syndrome, (15) inflammatory bowel disease, including Crohn's disease and ulcerative colitis, (16) other inflammatory conditions, (17) pancreatitis, (18) abdominal obesity, (19) neurodegenerative disease, (20) retinopathy, (21) nephropathy, (22) neuropathy, (23) Syndrome X, (24) ovarian hyperandrogenism (polycystic ovarian syndrome), and other disorders where insulin resistance is a component. In Syndrome X, also known as Metabolic Syndrome, obesity is thought to promote insulin resistance, diabetes, dyslipidemia, hypertension, and increased cardiovascular risk. Therefore, DPP-4 inhibitors may also be useful to treat hypertension associated with this condition.
Obesity
DPP-4 inhibitors may be useful for the treatment of obesity. This is based on the observed inhibitory effects on food intake and gastric emptying of GLP-1 and GLP-2. Exogenous administration of GLP-1 in humans significantly decreases food intake and slows gastric emptying (Am. J. Physiol., 277: R910-R916 (1999)). ICV administration of GLP-1 in rats and mice also has profound effects on food intake (Nature Medicine, 2: 1254-1258 (1996)). This inhibition of feeding is not observed in GLP-1R(−/−) mice, indicating that these effects are mediated through brain GLP-1 receptors. By analogy to GLP-1, it is likely that GLP-2 is also regulated by DPP-4. ICV administration of GLP-2 also inhibits food intake, analogous to the effects observed with GLP-1 (Nature Medicine, 6: 802-807 (2000)). In addition, studies with DPP-4 deficient mice suggest that these animals are resistant to diet-induced obesity and associated pathology (e.g. hyperinsulinonemia).
Cardiovascular Disease
GLP-1 has been shown to be beneficial when administered to patients following acute myocardial infarction, leading to improved left ventricular function and reduced mortality after primary angioplasty (Circulation, 109: 962-965 (2004)). GLP-1 administration is also useful for the treatment of left ventricular systolic dysfunction in dogs with dilated cardiomyopathy and ischemic induced left ventricular dysfunction, and thus may prove useful for the treatment of patients with heart failure (US2004/0097411). DPP-4 inhibitors are expected to show similar effects through their ability to stabilize endogenous GLP-1.
Growth Hormone Deficiency
DPP-4 inhibition may be useful for the treatment of growth hormone deficiency, based on the hypothesis that growth-hormone releasing factor (GRF), a peptide that stimulates release of growth hormone from the anterior pituitary, is cleaved by the DPP-4 enzyme in vivo (WO 00/56297). The following data provide evidence that GRF is an endogenous substrate: (1) GRF is efficiently cleaved in vitro to generate the inactive product GRF[3-44](BBA 1122: 147-153 (1992)); (2) GRF is rapidly degraded in plasma to GRF[3-44]; this is prevented by the DPP-4 inhibitor diprotin A; and (3) GRF[3-44] is found in the plasma of a human GRF transgenic pig (J. Clin. Invest., 83: 1533-1540 (1989)). Thus DPP-4 inhibitors may be useful for the same spectrum of indications which have been considered for growth hormone secretagogues.
Intestinal Injury
The potential for using DPP-4 inhibitors for the treatment of intestinal injury is suggested by the results of studies indicating that glucagon-like peptide-2 (GLP-2), a likely endogenous substrate for DPP-4, may exhibit trophic effects on the intestinal epithelium (Regulatory Peptides, 90: 27-32 (2000)). Administration of GLP-2 results in increased small bowel mass in rodents and attenuates intestinal injury in rodent models of colitis and enteritis.
Immunosuppression
DPP-4 inhibition may be useful for modulation of the immune response, based upon studies implicating the DPP-4 enzyme in T cell activation and in chemokine processing, and efficacy of DPP-4 inhibitors in vivo models of disease. DPP-4 has been shown to be identical to CD26, a cell surface marker for activated immune cells. The expression of CD26 is regulated by the differentiation and activation status of immune cells. It is generally accepted that CD26 functions as a co-stimulatory molecule in in vitro models of T cell activation. A number of chemokines contain proline in the penultimate position, presumably to protect them from degradation by non-specific aminopeptidases. Many of these have been shown to be processed in vitro by DPP-4. In several cases (RANTES, LD78-beta, MDC, eotaxin, SDF-1alpha), cleavage results in an altered activity in chemotaxis and signaling assays. Receptor selectivity also appears to be modified in some cases (RANTES). Multiple N-terminally truncated forms of a number of chemokines have been identified in vitro cell culture systems, including the predicted products of DPP-4 hydrolysis.
DPP-4 inhibitors have been shown to be efficacious immunosuppressants in animal models of transplantation and arthritis. Prodipine (Pro-Pro-diphenyl-phosphonate), an irreversible inhibitor of DPP-4, was shown to double cardiac allograft survival in rats from day 7 to day 14 (Transplantation, 63: 1495-1500 (1997)). DPP-4 inhibitors have been tested in collagen and alkyldiamine-induced arthritis in rats and showed a statistically significant attenuation of hind paw swelling in this model [Int. J. Immunopharmacology, 19:15-24 (1997) and Immunopharmacology, 40: 21-26 (1998)]. DPP-4 is upregulated in a number of autoimmune diseases including rheumatoid arthritis, multiple sclerosis, Graves' disease, and Hashimoto's thyroiditis (Immunology Today, 20: 367-375 (1999)).
HIV Infection
DPP-4 inhibition may be useful for the treatment or prevention of HIV infection or AIDS because a number of chemokines which inhibit HIV cell entry are potential substrates for DPP-4 (Immunology Today 20: 367-375 (1999)). In the case of SDF-1alpha, cleavage decreases antiviral activity (PNAS, 95: 6331-6 (1998)). Thus, stabilization of SDF-1alpha through inhibition of DPP-4 would be expected to decrease HIV infectivity.
Hematopoiesis
DPP-4 inhibition may be useful for the treatment or prevention of hematopiesis because DPP-4 may be involved in hematopoiesis. A DPP-4 inhibitor, Val-Boro-Pro, stimulated hematopoiesis in a mouse model of cyclophosphamide-induced neutropenia (WO 99/56753).
Neuronal Disorders
DPP-4 inhibition may be useful for the treatment or prevention of various neuronal or psychiatric disorders because a number of peptides implicated in a variety of neuronal processes are cleaved in vitro by DPP-4. A DPP-4 inhibitor thus may have a therapeutic benefit in the treatment of neuronal disorders. Endomorphin-2, beta-casomorphin, and substance P have all been shown to be in vitro substrates for DPP-4. In all cases, in vitro cleavage is highly efficient, with kcat/Km about 106 M−1s−1 or greater. In an electric shock jump test model of analgesia in rats, a DPP-4 inhibitor showed a significant effect that was independent of the presence of exogenous endomorphin-2 (Brain Research, 815: 278-286 (1999)). Neuroprotective and neuroregenerative effects of DPP-4 inhibitors were also evidenced by the inhibitors' ability to protect motor neurons from excitotoxic cell death, to protect striatal innervation of dopaminergic neurons when administered concurrently with MPTP, and to promote recovery of striatal innervation density when given in a therapeutic manner following MPTP treatment [see Yong-Q. Wu, et al., “Neuroprotective Effects of Inhibitors of Dipeptidyl peptidase-IV In Vitro and In Vivo,” Int. Conf. On Dipeptidyl Aminopeptidases: Basic Science and Clinical Applications, Sep. 26-29, 2002 (Berlin, Germany)].
Anxiety
Rats naturally deficient in DPP-4 have an anxiolytic phenotype (WO 02/34243; Karl et al., Physiol. Behav. 2003). DPP-4 deficient mice also have an anxiolytic phenotype using the porsolt and light/dark models. Thus DPP-4 inhibitors may prove useful for treating anxiety and related disorders.
Memory and Cognition
GLP-1 agonists are active in models of learning (passive avoidance, Morris water maze) and neuronal injury (kainate-induced neuronal apoptosis) as demonstrated by During et al. (Nature Med. 9: 1173-1179 (2003)). The results suggest a physiological role for GLP-1 in learning and neuroprotection. Stabilization of GLP-1 by DPP-4 inhibitors are expected to show similar effects
Myocardial Infarction
GLP-1 has been shown to be beneficial when administered to patients following acute myocardial infarction (Circulation, 109: 962-965 (2004)). DPP-4 inhibitors are expected to show similar effects through their ability to stabilize endogenous GLP-1.
Tumor Invasion and Metastasis
DPP-4 inhibition may be useful for the treatment or prevention of tumor invasion and metastasis because an increase or decrease in expression of several ectopeptidases including DPP-4 has been observed during the transformation of normal cells to a malignant phenotype (J. Exp. Med., 190: 301-305 (1999)). Up- or down-regulation of these proteins appears to be tissue and cell-type specific. For example, increased CD26/DPP-4 expression has been observed on T cell lymphoma, T cell acute lymphoblastic leukemia, cell-derived thyroid carcinomas, basal cell carcinomas, and breast carcinomas. Thus, DPP-4 inhibitors may have utility in the treatment of such carcinomas.
Benign Prostatic Hypertrophy
DPP-4 inhibition may be useful for the treatment of benign prostatic hypertrophy because increased DPP-4 activity was noted in prostate tissue from patients with BPH (Eur. J. Clin. Chem. Clin. Biochem., 30: 333-338 (1992)).
Sperm Motility/Male Contraception
DPP-4 inhibition may be useful for the altering sperm motility and for male contraception because in seminal fluid, prostatosomes, prostate derived organelles important for sperm motility, possess very high levels of DPP-4 activity (Eur. J. Clin. Chem. Clin. Biochem., 30: 333-338 (1992)).
Gingivitis
DPP-4 inhibition may be useful for the treatment of gingivitis because DPP-4 activity was found in gingival crevicular fluid and in some studies correlated with periodontal disease severity (Arch. Oral Biol. 37: 167-173 (1992)).
Osteoporosis
DPP-4 inhibition may be useful for the treatment or prevention of osteoporosis because GIP receptors are present in osteoblasts.
Stem Cell Transplantation
Inhibition of DPP-4 on donor stem cells has been shown to lead to an enhancement of their bone marrow homing efficiency and engraftment, and an increase in survival in mice (Christopherson, et al., Science, 305:1000-1003 (2004)). Thus DPP-4 inhibitors may be useful in bone marrow transplantation.
The compounds of the present invention have utility in treating or preventing one or more of the following conditions or diseases: (1) hyperglycemia, (2) low glucose tolerance, (3) insulin resistance, (4) obesity, (5) lipid disorders, (6) dyslipidemia, (7) hyperlipidemia, (8) hypertriglyceridemia, (9) hypercholesterolemia, (10) low HDL levels, (11) high LDL levels, (12) atherosclerosis and its sequalae, (13) vascular restenosis, (14) irritable bowel syndrome, (15) inflammatory bowel disease, including Crohn's disease and ulcerative colitis, (16) other inflammatory conditions, (17) pancreatitis, (18) abdominal obesity, (19) neurodegenerative disease, (20) retinopathy, (21) nephropathy, (22) neuropathy, (23) Syndrome X, (24) ovarian hyperandrogenism (polycystic ovarian syndrome), (25) Type 2 diabetes, (26) growth hormone deficiency, (27) neutropenia, (28) neuronal disorders, (29) tumor metastasis, (30) benign prostatic hypertrophy, (32) gingivitis, (33) hypertension, (34) osteoporosis, (35) anxiety, (36) memory deficit, (37) cognition deficit, (38) stroke, (39) Alzheimer's disease, and other conditions that may be treated or prevented by inhibition of DPP-4.
The compounds of the present invention are further useful in methods for the prevention or treatment of the aforementioned diseases, disorders and conditions in combination with other therapeutic agents.
Combination Therapy
The compounds of the present invention may be used in combination with one or more other drugs in the treatment, prevention, suppression or amelioration of diseases or conditions for which compounds of Formula I, Ia, II or III or the other drugs may have utility, where the combination of the drugs together are safer or more effective than either drug alone. Such other drug(s) may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of Formula I, Ia, II or III. When a compound of Formula I, Ia, II or III is used contemporaneously with one or more other drugs, a pharmaceutical composition in unit dosage form containing such other drugs and the compound of Formula I, Ia, II or III is preferred, particularly in combination with a pharmaceutically acceptable carrier. However, the combination therapy may also include therapies in which the compound of Formula I, Ia, II or III and one or more other drugs are administered on different overlapping schedules. It is also contemplated that when used in combination with one or more other active ingredients, the compounds of the present invention and the other active ingredients may be used in lower doses than when each is used singly. Accordingly, the pharmaceutical compositions of the present invention include those that contain one or more other active ingredients, in addition to a compound of Formula I, Ia, II or III.
When a compound of the present invention is used contemporaneously with one or more other drugs, a pharmaceutical composition containing such other drugs in addition to the compound of the present invention is preferred. Accordingly, the pharmaceutical compositions of the present invention include those that also contain one or more other active ingredients, in addition to a compound of the present invention.
The weight ratio of the compound of the present invention to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used. Thus, for example, when a compound of the present invention is combined with another agent, the weight ratio of the compound of the present invention to the other agent will generally range from about 1000:1 to about 1:1000, preferably about 200:1 to about 1:200. Combinations of a compound of the present invention and other active ingredients will generally also be within the aforementioned range, but in each case, an effective dose of each active ingredient should be used.
In such combinations the compound of the present invention and other active agents may be administered separately or in conjunction. In addition, the administration of one element may be prior to, concurrent to, or subsequent to the administration of other agent(s).
Examples of other active ingredients that may be administered in combination with a compound of Formula I, Ia, II or III, and either administered separately or in the same pharmaceutical composition, include, but are not limited to:
(1) insulin sensitizers, including (i) PPARγ agonists, such as the glitazones (e.g. pioglitazone, rosiglitazone, netoglitazone, rivoglitazone, and balaglitazone) and other PPAR ligands, including (1) PPARα/γ dual agonists, such as muraglitazar, aleglitazar, sodelglitazar, and naveglitazar, (2) PPARα agonists, such as fenofibric acid derivatives (gemfibrozil, clofibrate, ciprofibrate, fenofibrate and bezafibrate), (3) selective PPARγ modulators (SPPARγM's), such as those disclosed in WO 02/060388, WO 02/08188, WO 2004/019869, WO 2004/020409, WO 2004/020408, and WO 2004/066963, and (4) PPARγ partial agonists; (ii) biguanides, such as metformin and its pharmaceutically acceptable salts, in particular, metformin hydrochloride, and extended-release formulations thereof, such as Glumetza®, Fortamet®, and GlucophageXR®; (iii) protein tyrosine phosphatase-1B (PTP-1B) inhibitors;
(2) insulin and insulin analogs or derivatives, such as insulin lispro, insulin detemir, insulin glargine, insulin glulisine, and inhalable formulations of each thereof;
(3) leptin and leptin derivatives, agonists, and analogs, such as metreleptin;
(4) amylin; amylin analogs, such as davalintide; and amylin agonists, such as pramlintide;
(5) sulfonylurea and non-sulfonylurea insulin secretagogues, such as tolbutamide, glyburide, glipizide, glimepiride, mitiglinide, and meglitinides, such as nateglinide and repaglinide;
(6) α-glucosidase inhibitors (such as acarbose, voglibose and miglitol);
(7) glucagon receptor antagonists, such as those disclosed in WO 98/04528, WO 99/01423, WO 00/39088, and WO 00/69810;
(8) incretin mimetics, such as GLP-1, GLP-1 analogs, derivatives, and mimetics (See for example, WO 2008/011446, U.S. Pat. No. 5,545,618, U.S. Pat. No. 6,191,102, and US56583111); and GLP-1 receptor agonists, such as oxyntomodulin and its analogs and derivatives (See for example, WO 2003/022304, WO 2006/134340, WO 2007/100535), glucagon and its analogs and derivatives (See for example, WO 2008/101017), exenatide, liraglutide, taspoglutide, albiglutide, AVE0010, CJC-1134-PC, NN9535, LY2189265, LY2428757, and BIM-51077, including intranasal, transdermal, and once-weekly formulations thereof, such as exenatide QW;
(9) LDL cholesterol lowering agents such as (i) C (lovastatin, simvastatin, pravastatin, cerivastatin, fluvastatin, atorvastatin, pitavastatin, and rosuvastatin), (ii) bile acid sequestering agents (such as cholestyramine, colestimide, colesevelam hydrochloride, colestipol, and dialkylaminoalkyl derivatives of a cross-linked dextran, (iii) inhibitors of cholesterol absorption, such as ezetimibe, and (iv) acyl CoA:cholesterol acyltransferase inhibitors, such as avasimibe;
(10) HDL-raising drugs, such as niacin or a salt thereof and extended-release versions thereof; MK-524A, which is a combination of niacin extended-release and the DP-1 antagonist MK-524; and nicotinic acid receptor agonists;
(11) antiobesity compounds;
(12) agents intended for use in inflammatory conditions, such as aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, and selective cyclooxygenase-2 (COX-2) inhibitors;
(13) antihypertensive agents, such as ACE inhibitors (such as enalapril, lisinopril, ramipril, captopril, quinapril, and tandolapril), A-II receptor blockers (such as losartan, candesartan, irbesartan, olmesartan medoxomil, valsartan, telmisartan, and eprosartan), renin inhibitors (such as aliskiren), beta blockers (such as and calcium channel blockers (such as;
(14) glucokinase activators (GKAs), such as LY2599506;
(15) inhibitors of 11β-hydroxysteroid dehydrogenase type 1, such as those disclosed in U.S. Pat. No. 6,730,690; WO 03/104207; and WO 04/058741;
(16) inhibitors of cholesteryl ester transfer protein (CETP), such as torcetrapib and MK-0859;
(17) inhibitors of fructose 1,6-bisphosphatase, such as those disclosed in U.S. Pat. Nos. 6,054,587; 6,110,903; 6,284,748; 6,399,782; and 6,489,476;
(18) inhibitors of acetyl CoA carboxylase-1 or 2 (ACC1 or ACC2);
(19) AMP-activated Protein Kinase (AMPK) activators;
(20) agonists of the G-protein-coupled receptors: GPR-109, GPR-116, GPR-119, and GPR-40;
(21) SSTR3 antagonists, such as those disclosed in WO 2009/011836;
(22) neuromedin U receptor 1 (NMUR1) and/or neuromedin U receptor 2 (NMUR2) agonists, such as those disclosed in WO2007/109135 and WO2009/042053, including, but not limited to, neuromedin U (NMU) and neuromedin S (NMS) and their analogs and derivatives;
(23) inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD);
(24) GPR-105 (P2YR14) antagonists, such as those disclosed in WO 2009/000087;
(25) inhibitors of glucose uptake, such as sodium-glucose transporter (SGLT) inhibitors and its various isoforms, such as SGLT-1; SGLT-2, such as dapagliflozin, tofogliflozin, sergliflozin, AVE2268, and remogliflozin; and SGLT-3;
(26) inhibitors of acyl coenzyme A:diacylglycerol acyltransferase 1 and 2 (DGAT-1 and DGAT-2) such as PF-04620110 (Pfizer);
(27) inhibitors of fatty acid synthase;
(28) inhibitors of acyl coenzyme A:monoacylglycerol acyltransferase 1 and 2 (MGAT-1 and MGAT-2);
(29) agonists of the TGR5 receptor (also known as GPBAR1, BG37, GPCR19, GPR131, and M-BAR);
(30) bromocriptine mesylate and rapid-release formulations thereof;
(31) histamine H3 receptor agonists; and
(32) α2-adrenergic or β3-adrenergic receptor agonists.
Antiobesity compounds that can be combined with compounds of Formula I, Ia, II or III include topiramate; zonisamide; naltrexone; phentermine; bupropion; the combination of bupropion and naltrexone; the combination of bupropion and zonisamide; the combination of topiramate and phentermine; fenfluramine; dexfenfluramine; sibutramine; lipase inhibitors, such as orlistat and cetilistat; melanocortin receptor agonists, in particular, melanocortin-4 receptor agonists; CCK-1 agonists; melanin-concentrating hormone (MCH) receptor antagonists; neuropeptide Y1 or Y5 antagonists (such as MK-0557); CB1 receptor inverse agonists and antagonists (such as rimonabant and taranabant); β3 adrenergic receptor agonists; ghrelin antagonists; bombesin receptor agonists (such as bombesin receptor subtype-3 agonists); histamine H3 receptor inverse agonists; 5-hydroxytryptamine-2c (5-HT2c) agonists, such as lorcaserin; and inhibitors of fatty acid synthase (FAS). For a review of anti-obesity compounds that can be combined with compounds of the present invention, see S. Chaki et al., “Recent advances in feeding suppressing agents: potential therapeutic strategy for the treatment of obesity,” Expert Opin. Ther. Patents, 11: 1677-1692 (2001); D. Spanswick and K. Lee, “Emerging antiobesity drugs,” Expert Opin. Emerging Drugs, 8: 217-237 (2003); J. A. Fernandez-Lopez, et al., “Pharmacological Approaches for the Treatment of Obesity,” Drugs, 62: 915-944 (2002); and K. M. Gadde, et al., “Combination pharmaceutical therapies for obesity,” Exp. Opin. Pharmacother., 10: 921-925 (2009).
Glucagon receptor antagonists that can be used in combination with the compounds of Formula I, Ia, II or III include, but are not limited to:

    N-[4-((1S)-1-{3-(3,5-dichlorophenyl)-5-[6-(trifluoromethoxy)-2-naphthyl]-1H-pyrazol-1-yl}ethyl)benzoyl]-β-alanine;
    N-[4-((1R)-1-{3-(3,5-dichlorophenyl)-5-[6-(trifluoromethoxy)-2-naphthyl]-1H-pyrazol-1-yl}ethyl)benzoyl]-β-alanine;
    N-(4-{1-[3-(2,5-dichlorophenyl)-5-(6-methoxy-2-naphthyl)-1H-pyrazol-1-yl]ethyl}benzoyl)-β-alanine;
    N-(4-{(1S)-1-[3-(3,5-dichlorophenyl)-5-(6-methoxy-2-naphthyl)-1H-pyrazol-1-yl]ethyl}benzoyl)-β-alanine;
    N-(4-{(1S)-1-[(R)-(4-chlorophenyl)(7-fluoro-5-methyl-1H-indol-3-yl)methyl]butyl}benzoyl)-β-alanine; and
    N-(4-{(1S)-1-[(4-chlorophenyl)(6-chloro-8-methylquinolin-4-yl)methyl]butyl}benzoyl)-β-alanine; and

pharmaceutically acceptable salts thereof.



Inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD) that can be used in combination with the compounds of Formula I, Ia, II or III include, but are not limited to:

    [5-(5-{4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl}-1,3,4-thiadiazol-2-yl)-2H-tetrazol-2-yl]acetic acid;
    (2′-{4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl}-2,5′-bi-1,3-thiazol-4-yl)acetic acid;
    (5-{3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]isoxazol-5-yl}-2H-tetrazol-2-yl)acetic acid;
    (3-{3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,2,4-oxadiazol-5-yl}-1H-pyrrol-1-yl)acetic acid;
    (5-{5-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]pyrazin-2-yl}-2H-tetrazol-2-yl)acetic acid; and
    (5-{2-[4-(5-bromo-2-chlorophenoxy)piperidin-1-yl]pyrimidin-5-yl}-2H-tetrazol-2-yl)acetic acid; and

pharmaceutically acceptable salts thereof.



Glucokinase activators that can be used in combination with the compounds of Formula I, Ia, II or III include, but are not limited to:

    3-(6-ethanesulfonylpyridin-3-yloxy)-5-(2-hydroxy-1-methyl-ethoxy)-N-(1-methyl-1H-pyrazol-3-yl)benzamide;
    5-(2-hydroxy-1-methyl-ethoxy)-3-(6-methanesulfonylpyridin-3-yloxy)-N-(1-methyl-1H-pyrazol-3-yl)benzamide;
    5-(1-hydroxymethyl-propoxy)-3-(6-methanesulfonylpyridin-3-yloxy)-N-(1-methyl-1H-pyrazol-3-yl)benzamide;
    3-(6-methanesulfonylpyridin-3-yloxy)-5-(1-methoxymethyl-propoxy)-N-(1-methyl-1H-pyrazol-3-yl)benzamide;
    5-isopropoxy-3-(6-methanesulfonylpyridin-3-yloxy)-N-(1-methyl-1H-pyrazol-3-yl)benzamide;
    5-(2-fluoro-1-fluoromethyl-ethoxy)-3-(6-methanesulfonylpyridin-3-yloxy)-N-(1-methyl-1H-pyrazol-3-yl)benzamide;
    3-({4-[2-(dimethylamino)ethoxy]phenyl}thio)-N-(3-methyl-1,2,4-thiadiazol-5-yl)-6-[(4-methyl-4H-1,2,4-triazol-3-yl)thio]pyridine-2-carboxamide;
    3-({4-[(1-methylazetidin-3-yl)oxy]phenyl}thio)-N-(3-methyl-1,2,4-thiadiazol-5-yl)-6-[(4-methyl-4H-1,2,4-triazol-3-yl)thio]pyridine-2-carboxamide;
    N-(3-methyl-1,2,4-thiadiazol-5-yl)-6-[(4-methyl-4H-1,2,4-triazol-3-yl)thio]-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]thio}pyridine-2-carboxamide; and
    3-[(4-{2-[(2R)-2-methylpyrrolidin-1-yl]ethoxy}phenyl)thio-N-(3-methyl-1,2,4-thiadiazol-5-yl)-6-[(4-methyl-4H-1,2,4-triazol-3-yl)thio]pyridine-2-carboxamide; and pharmaceutically acceptable salts thereof.


Agonists of the GPR-119 receptor that can be used in combination with the compounds of Formula I, Ia, II or III include, but are not limited to:

    rac-cis 5-chloro-2-{4-[2-(2-{[5-(methylsulfonyl)pyridin-2-yl]oxy}ethyl)cyclopropyl]piperidin-1-yl}pyrimidine;
    5-chloro-2-{4-[(1R,2S)-2-(2-{[5-(methylsulfonyl)pyridin-2-yl]oxy}ethyl)cyclopropyl]piperidin-1-yl}pyrimidine;
    rac cis-5-chloro-2-[4-(2-{2-[4-(methylsulfonyl)phenoxy]ethyl}cyclopropyl)piperidin-1-yl]pyrimidine;
    5-chloro-2-[4-((1S,2R)-2-{2-[4-(methylsulfonyl)phenoxy]ethyl}cyclopropyl)piperidin-1-yl]pyrimidine;
    5-chloro-2-[4-((1R,2S)-2-{2-[4-(methylsulfonyl)phenoxy]ethyl}cyclopropyl)piperidin-1-yl]pyrimidine;
    rac cis-5-chloro-2-[4-(2-{2-[3-(methylsulfonyl)phenoxy]ethyl}cyclopropyl)piperidin-1-yl]pyrimidine; and
    rac cis-5-chloro-2-[4-(2-{2-[3-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy]ethyl}cyclopropyl)piperidin-1-yl]pyrimidine; and

pharmaceutically acceptable salts thereof.



Selective PPARγ modulators (SPPARγM's) that can be used in combination with the compounds of Formula I, Ia, II or III include, but are not limited to:

    (2S)-2-({6-chloro-3-[6-(4-chlorophenoxy)-2-propylpyridin-3-yl]-1,2-benzisoxazol-5-yl}oxy)propanoic acid;
    (2S)-2-({6-chloro-3-[6-(4-fluorophenoxy)-2-propylpyridin-3-yl]-1,2-benzisoxazol-5-yl}oxy)propanoic acid;
    (2S)-2-{[6-chloro-3-(6-phenoxy-2-propylpyridin-3-yl)-1,2-benzisoxazol-5-yl]oxy}propanoic acid;
    (2R)-2-({6-chloro-3-[6-(4-chlorophenoxy)-2-propylpyridin-3-yl]-1,2-benzisoxazol-5-yl}oxy)propanoic acid;
    (2R)-2-{3-[3-(4-methoxy)benzoyl-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]phenoxy}butanoic acid;
    (2S)-2-{3-[3-(4-methoxy)benzoyl-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]phenoxy}butanoic acid;
    2-{3-[3-(4-methoxy)benzoyl-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]phenoxy}-2-methylpropanoic acid; and
    (2R)-2-{3-[3-(4-chloro)benzoyl-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]phenoxy}propanoic acid; and

pharmaceutically acceptable salts thereof.



Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 that can be used in combination with the compounds of Formula I, Ia, II or III include, but are not limited to:

    3-[1-(4-chlorophenyl)-trans-3-fluorocyclobutyl]-4,5-dicyclopropyl-r-4H-1,2,4-triazole;
    3-[1-(4-chlorophenyl)-trans-3-fluorocyclobutyl]-4-cyclopropyl-5-(1-methylcyclopropyl)-r-4H-1,2,4-triazole;
    3-[1-(4-chlorophenyl)-trans-3-fluorocyclobutyl]-4-methyl-5-[2-(trifluoromethoxy)phenyl]-r-4H-1,2,4-triazole;
    3-[1-(4-chlorophenyl)cyclobutyl]-4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazole;
    3-{4-[3-(ethylsulfonyl)propyl]bicyclo[2.2.2]oct-1-yl}-4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazole;
    4-methyl-3-{4-[4-(methylsulfonyl)phenyl]bicyclo[2.2.2]oct-1-yl}-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazole;
    3-(4-{4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-3-yl}bicyclo[2.2.2]oct-1-yl)-5-(3,3,3-trifluoropropyl)-1,2,4-oxadiazole;
    3-(4-{4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-3-yl}bicyclo[2.2.2]oct-1-yl)-5-(3,3,3-trifluoroethyl)-1,2,4-oxadiazole;
    5-(3,3-difluorocyclobutyl)-3-(4-{4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-3-yl}bicyclo[2.2.2]oct-1-yl)-1,2,4-oxadiazole;
    5-(1-fluoro-1-methylethyl)-3-(4-{4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-3-yl}bicyclo[2.2.2]oct-1-yl)-1,2,4-oxadiazole;
    2-(1,1-difluoroethyl)-5-(4-{4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-3-yl}bicyclo[2.2.2]oct-1-yl)-1,3,4-oxadiazole;
    2-(3,3-difluorocyclobutyl)-5-(4-{4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-3-yl}bicyclo[2.2.2]oct-1-yl)-1,3,4-oxadiazole; and
    5-(1-difluoroethyl)-3-(4-{4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-3-yl}bicyclo[2.2.2]oct-1-yl)-1,2,4-oxadiazole; and

pharmaceutically acceptable salts thereof.



Somatostatin subtype receptor 3 (SSTR3) antagonists that can be used in combination with the compounds of Formula I, Ia, II or III include, but are not limited to:







and pharmaceutically acceptable salts thereof.

AMP-activated Protein Kinase (AMPK) activators that can be used in combination with the compounds of Formula I, Ia, II or III include, but are not limited to:







and pharmaceutically acceptable salts thereof.

Inhibitors of acetyl-CoA carboxylase-1 and 2 (ACC-1 and ACC-2) that can be used in combination with the compounds of Formula I, Ia, II or III include, but are not limited to:

    3-{1′-[(1-cyclopropyl-4-methoxy-1H-indol-6-yl)carbonyl]-4-oxospiro[chroman-2,4′-piperidin]-6-yl}benzoic acid;
    5-{1′-[(1-cyclopropyl-4-methoxy-1H-indol-6-yl)carbonyl]-4-oxospiro[chroman-2,4′-piperidin]-6-yl}nicotinic acid;
    1′-[(1-cyclopropyl-4-methoxy-1H-indol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one;
    1′-[(1-cyclopropyl-4-ethoxy-3-methyl-1H-indol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one;
    5-{1′-[(1-cyclopropyl-4-methoxy-3-methyl-1H-indol-6-yl)carbonyl]-4-oxo-spiro[chroman-2,4′-piperidin]-6-yl}nicotinic acid;
    4′-({6-(5-carbamoylpyridin-2-yl)-4-oxospiro[chroman-2,4′-piperidin]-1′-yl}carbonyl)-2′,6′-diethoxybiphenyl-4-carboxylic acid;
    2′,6′-diethoxy-4′-{[6-(1-methyl-1H-pyrazol-4-yl)-4-oxospiro[chroman-2,4′-piperidin]-1′-yl]carbonyl}biphenyl-4-carboxylic acid;
    2′,6′-diethoxy-3-fluoro-4′-{[6-(1-methyl-1H-pyrazol-4-yl)-4-oxospiro[chroman-2,4′-piperidin]-1′-yl]carbonyl}biphenyl-4-carboxylic acid;
    5-[4-({6-(3-carbamoylphenyl)-4-oxospiro[chroman-2,4′-piperidin]-1′-yl}carbonyl)-2,6-diethoxyphenyl]nicotinic acid;
    sodium 4′-({6-(5-carbamoylpyridin-2-yl)-4-oxospiro[chroman-2,4′-piperidin]-1′-yl}carbonyl)-2′,6′-diethoxybiphenyl-4-carboxylate;
    methyl 4′-({6-(5-carbamoylpyridin-2-yl)-4-oxospiro[chroman-2,4′-piperidin]-1′-yl}carbonyl)-2′,6′-diethoxybiphenyl-4-carboxylate;
    1′-[(4,8-dimethoxyquinolin-2-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one;
    (5-{1′-[(4,8-dimethoxyquinolin-2-yl)carbonyl]-4-oxospiro[chroman-2,4′-piperidin]-6-yl}-2H-tetrazol-2-yl)methyl pivalate;
    5-{1′-[(8-cyclopropyl-4-methoxyquinolin-2-yl)carbonyl]-4-oxospiro[chroman-2,4′-piperidin]-6-yl}nicotinic acid;
    1′-(8-methoxy-4-morpholin-4-yl-2-naphthoyl)-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one; and
    1′-[(4-ethoxy-8-ethylquinolin-2-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4′-piperidin]-4-one; and

pharmaceutically acceptable salts and esters thereof.

Methods of Administration



The compounds of the present invention may be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, ICV, intracisternal injection or infusion, subcutaneous injection, or implant), by inhalation spray, nasal, vaginal, rectal, sublingual, or topical routes of administration and may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles appropriate for each route of administration. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, monkeys, etc., the compounds of the invention are effective for use in humans.
The pharmaceutical compositions for the administration of the compounds of this invention may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general, the pharmaceutical compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation. In the pharmaceutical composition the active object compound is included in an amount sufficient to produce the desired effect upon the process or condition of diseases. As used herein, the term “composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the U.S. Pat. Nos. 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.
Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.
Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
The compounds of the present invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.
For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of the present invention are employed. (For purposes of this application, topical application shall include mouthwashes and gargles.)
The pharmaceutical composition and method of the present invention may further comprise other therapeutically active compounds as noted herein which are usually applied in the treatment of the above mentioned pathological conditions.
In the treatment or prevention of conditions which require inhibition of dipeptidyl peptidase-IV enzyme activity an appropriate dosage level will generally be about 0.01 to 500 mg per kg patient body weight per day which can be administered in single or multiple doses. Preferably, the dosage level will be about 0.1 to about 250 mg/kg per day; more preferably about 0.5 to about 100 mg/kg per day. A suitable dosage level may be about 0.01 to 250 mg/kg per day, about 0.05 to 100 mg/kg per day, or about 0.1 to 50 mg/kg per day. Within this range the dosage may be 0.05 to 0.5, 0.5 to 5 or 5 to 50 mg/kg per day. For oral administration, the compositions are preferably provided in the form of tablets containing 1.0 to 1000 mg of the active ingredient, particularly 1.0, 5.0, 10.0, 15.0. 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0, 900.0, and 1000.0 mg of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.
When treating or preventing diabetes mellitus and/or hyperglycemia or hypertriglyceridemia or other diseases for which compounds of the present invention are indicated, generally satisfactory results are obtained when the compounds of the present invention are administered at a daily dosage of from about 0.1 mg to about 100 mg per kilogram of animal body weight, preferably given as a single daily dose or in divided doses two to six times a day, or in sustained release form. For most large mammals, the total daily dosage is from about 1.0 mg to about 1000 mg, preferably from about 1 mg to about 50 mg. In the case of a 70 kg adult human, the total daily dose will generally be from about 7 mg to about 350 mg. This dosage regimen may be adjusted to provide the optimal therapeutic response.
It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
Synthetic methods for preparing the compounds of the present invention are illustrated in the following Schemes and Examples. Starting materials are commercially available or may be made according to procedures know in the art or as illustrated herein.
The intermediates and compounds of structural Formula I, Ia, II or III of the present invention can be prepared according to the procedures of the following Schemes and Examples using appropriate materials and are further exemplified by the following specific examples. These specific examples are provided so that the invention might be more fully understood and are to be considered illustrative only and should not be construed as limiting the invention in any way. The Examples further illustrate details for the preparation of the compounds of the present invention. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds. All temperatures are degrees Celsius unless otherwise noted. Mass spectra (MS) were measured by electron-spray ion-mass spectroscopy. Proton NMR (H-NMR) spectra were measured at 400 or 500 MHz, as indicated, and chemical shifts are provided as parts-per-million (ppm).
EXAMPLES







Example 1




To a 70° C. mixture of 6-amino-1-methyluracil (28.00 g, 198.40 mmol), sodium acetate (16.27 g, 198.40 mmol), and water (99 mL) was added a mixture of chloroacetaldehyde (93.44 g of a 50 wt % solution in water, 595.20 mmol), sodium acetate (16.27 g, 198.40 mmol) and water (30 mL). This mixture was stirred at 70° C. for 2 hr and then placed in an ice bath. The reaction mixture was filtered and washed with cold water. The solid was then dried in vacuo at 60° C. to afford compound 3 as a beige solid. This material was used without further purification. 1HNMR (DMSO-d6, 500 MHz)  11.65 (s, 1H), 10.71 (s, 1H), 6.81 (m, 1H), 6.31 (m, 1H), 3.35 (s, 3H).
To a room temperature solution of crude compound 3 (23.68 g) in anhydrous DMSO (574 mL) was added sodium hydride (5.73 g, 60% dispersion), portion-wise. This mixture was stirred for 35 min., followed by addition of di-tert-butyl dicarbonate (33 mL) at room temperature. The reaction mixture was quenched over ice-water (1 L) after 15 hr. The resulting solid was filtered and washed with ice-water. The solid was dried in vacuo to afford compound 4 as a beige solid. This material was used without further purification. 1HNMR (DMSO-d6, 500 MHz)  11.29 (s, 1H), 7.10 (d, 1H), 66.50 (s, 1H), 3.33 (s, 6H), 1.58 (s, 9H); MS (M+1)+ m/z calcd for C12H16N3O4+=266.1. found m/z=265.9.
Two 1 L round-bottomed flasks were each charged with crude compound 4 (11.5 g), 2-(bromomethyl)-4-fluorobenzonitrile (12.1 g), K2CO3 (7.82 g), and anhydrous DMSO (377 mL). Each reaction mixture was poured over ice-water (600 mL) after stirring at room temperature for 16 hr, and then each resulting mixture was filtered. The isolated solids were washed with ice-water, combined, and dried in vacuo at 60° C. to afford compound 5 as a beige solid. This material was used without further purification. 1HNMR (DMSO-d6, 500 MHz) δ 7.66 (m, 1H), 7.05-6.97 (m, 3H), 6.62 (d, 1H), 5.41 (s, 2H), 3.55 (s, 3H), 1.64 (s, 9H); MS (M+1)+ m/z calcd for C20H20FN4O4+=399.1. found m/z=398.7.
To a 0° C. solution of crude compound 5 (30.64 g) in anhydrous CH2Cl2 (538 mL) and under N2 was added trifluoroacetic acid (135 mL). The reaction stirred for 30 min. at 0° C. and then at room temperature for 16 hr. The reaction was concentrated in vacuo, suspended in EtOAc, and neutralized with saturated aq. NaHCO3. The mixture was extracted with EtOAc, dried over Na2SO4, and concentrated in vacuo. The solid that did not dissolve during the extraction was filtered and combined with the organic layer from the extraction. This material was concentrated in vacuo at 65° C. to afford compound 6 as a green/gray solid. This material was used without further purification. 1HNMR (DMSO-d6, 500 MHz)  11.85 (s, 1H), 7.95 (m, 1H), 7.31 (d, 1H), 7.07 (m, 1H), 6.82 (d, 1H), 6.40 (d, 1H), 5.21 (s, 2H), 3.44 (s, 3H); MS (M+1)+ m/z calcd for C15H12FN4O2+=299.1. found m/z=299.8.
To a round bottom containing crude compound 6 (23.19 g) and under N2 was added POCl3 (186 mL). The round bottom was immediately equipped with a condenser and placed in an oil-bath set to 105° C. The reaction was stirred at 105° C. for 50 min., cooled to near room temperature, and then concentrated in vacuo to afford a solid. To this resulting solid at room temperature and under N2 was added anhydrous DMF (373 mL) and (R)-3-(Boc-amino)piperidine (34.4 g). The reaction was quenched over ice-water (800 mL) after stirring at room temperature for 15 hr. The resulting mixture was filtered. The filtrate was neutralized with saturated aq. NaHCO3 and extracted with CH2Cl2. The isolated solid was suspended in water (200 mL), and then this mixture was neutralized with saturated aq. NaHCO3. and extracted with CH2Cl2. The combined organic layers were washed with brine, dried over Na2SO4 and concentrated in vacuo to afford compound 7 as a black solid. This material was used without further purification. MS (M+1)+ m/z calcd for C25H30FN6O3+=481.2. found m/z=481.2.
To a 0° C. mixture of crude compound 7 (32.33 g) in anhydrous CH2Cl2 (228 mL) and under N2 was added trifluoroacetic acid (57 mL), drop-wise. The reaction stirred for 15 min. at 0° C. and then at room temperature for 15 hr. The reaction was concentrated in vacuo, diluted with CH2Cl2, neutralized with saturated aq. NaHCO3, extracted with CH2Cl2, and concentrated in vacuo to obtain 25.75 g of a dark brown foam. A portion of this material was then purified by reverse phase chromatography with water/acetonitile/0.1% trifluoroacetic acid, then by supercritical fluid chromatography with ethanol/0.1% diisopropylamine, and then by reverse phase chromatography with water/acetonitile/0.1% trifluoroacetic acid to afford Example 1 as a yellow foam. 1HNMR (CDCl3, 400 MHz)  7.70 (m, 1H), 7.25 (d, 1H), 7.09 (m, 1H), 6.80 (m, 1H), 6.51 (d, 1H), 5.44 (m, 2H), 3.71 (s, 3H), 3.49 (m, 1H), 3.36 (m, 1H), 3.07 (m, 1H), 2.97 (m, 2H), 2.04 (m, 1H), 1.82 (m, 1H), 1.68-1.48 (m, 3H), 1.33 (m, 1H); MS (M+1)+ m/z calcd for C20H22FN6O+=381.2. found m/z=381.2.
Example 2




Example 2 was synthesized by a method similar to that outlined for Example 1. Data for Example 2: MS (M+1)+ m/z calcd for C20H23N6O+=363.2. found m/z=363.2.
Example 3




Example 3 was synthesized by a method similar to that outlined for Example 1. Data for Example 3: 1HNMR (CDCl3, 500 MHz) δ 7.23 (d, 1H), δ 7.02 (m, 1H), δ 6.94 (m, 1H), δ 6.78 (m, 1H), δ 6.49 (d, 1H), δ 5.27 (m, 2H), δ 3.71 (s, 3H), δ 3.49 (m, 1H), δ 3.37 (m, 1H), 3.07 (m, 1H), δ 2.96 (m, 1H), δ 2.85 (m, 1H), δ 2.03 (m, 1H), δ 1.83 (m, 1H), δ 1.66 (m, 1H), δ 1.32-1.20 (m, 3H); MS (M+1)+ m/z calcd for C19H22F2N5O+=374.2. found m/z=374.2.
Example 4




Example 4 was synthesized by a method similar to that outlined for Example 1. Data for Example 4: 1HNMR (CDCl3, 500 MHz) δ 7.27 (m, 1H), δ 7.24 (d, 1H), δ 6.95 (m, 2H), δ 6.88 (9, 1H), δ 6.49 (d, 1H), δ 5.27 (br s, 2H), δ 3.71 (s, 3H), δ 3.48 (m, 1H), δ 3.42 (m, 1H), δ 3.07 (m, 1H), δ 2.95 (m, 1H), δ 2.83 (m, 1H), δ 2.02 (m, 1H), δ 1.83 (m, 1H), δ 1.64 (m, 1H), δ 1.30 (m, 1H), δ 1.15-1.10 (br s, 2H); MS (M+1)+ m/z calcd for C19H23FN5O+=356.2. found m/z=356.2.




Example 5




To a room temperature mixture of heterocycle 4 (8.40 g, 31.7 mmol) in CH2Cl2 (160 mL) was added N-chlorosuccinimide (4.65 g, 1.1 equiv.), and then this mixture was placed in a 40° C. oil bath. After 1.25 h, additional heterocycle 4 (3.00 g, 11.3 mmol) and N-chlorosuccinimide (1.66 g) were added to the reaction mixture. After stirring overnight at 40° C., the reaction mixture was absorbed onto silica gel and purified by silica gel chromatography (aq. NH4OH/methanol/CH2Cl2) to afford a light brown solid, which was a mixture of desired product 8 and an impurity, in a 5:6 ratio, respectively. This material was used without additional purification. 1HNMR (DMSO-d6, 500 MHz) δ 6.64 (s, 1H), 5.75 (s, 1H), 2.61 (s, 3H), 1.62 (s, 9H); MS (M+Na)+ m/z calcd for C12H14ClN3O4Na=322.1. found m/z=322.0.
Alternate isolation procedure starting with 22.1 g of 4: The reaction solution (4 and N-chlorosuccinimide and 400 mL of CH2Cl2) was cooled, resulting in the formation of a solid. This mixture was diluted with CH2Cl2 (500 mL) and methanol (50 mL), and then washed with a mixture of saturated aq. NaHCO3 (500 mL) and aq. 10% Na2S2O3 (50 mL). The layers were separated, and then the aq. layer was extracted with CH2Cl2 (2×250 mL). The combined organic layers were washed with saturated aq. NaHCO3 (3×250 mL), dried over Na2SO4, filtered, concentrated under reduced pressure, and dried under house vacuum at 60° C. overnight to afford 19.79 g of desired product 8 as a brown solid.
A flask was charged with crude heterocycle 8 (10.88 g), 2-cyano-5-fluorobenzyl bromide (13.6 g), powdered K2CO3 (8.8 g), and then DMSO (100 mL). This mixture was stirred at room temperature for 2.25 h, and then purified by reverse phase chromatography (800 g C18 cartridge, CH3CN/H2O/0.1% HCO2H) to afford a tan solid that consisted of heterocycle 9 along with minor impurities. This material was used without additional purification. 1HNMR (CD3OD, 500 MHz) δ 7.78 (dd, 1H), 7.18 (ddd, 1H), 7.10 (dd, 1H), 6.57 (s, 1H), 5.34 (s, 2H), 3.48 (s, 3H), 1.68 (s, 9H); MS (M+Na)+ m/z calecd for C20H18ClFN4O4Na=455.1. found m/z=455.0.
To a 0° C. suspension of crude heterocycle 9 (7.0 g) in CH2Cl2 (115 mL, 0.25 M) was added trifluoroacetic acid (12 mL, 2.5 M). After several minutes, the cooling bath was removed. After being stirred at room temperature for 17.5 h, this solution was concentrated under reduced pressure. The resulting residue was stirred with a mixture of CH2Cl2 (50 mL) and saturated aq. NaHCO3 (200 mL) for 1 h. This mixture was filtered, and then the isolated solid was washed with H2O (2 times), air dried, transferred to a flask, and dried under house vacuum at 50° C. for 3 days to afford the desired product 10 as a gray solid. 1HNMR (DMSO-d6, 500 MHz) δ 12.65 (br s, 1H), 7.96 (dd, 1H), 7.33 (ddd, 1H), 7.09 (dd, 1H), 6.44 (d, 1H), 5.20 (s, 2H), 3.48 (s, 3H); MS (M+Na)+ m/z calcd for C15H11ClFN4O4Na=333.1. found m/z=333.0.
A 25 mL round bottom flask was charged with a stirbar and fitted with a reflux condenser. This reaction apparatus was flame dried under house vacuum. The cooled round bottom was charged with heterocycle 10 (1.0 g, 3.01 mmol) and POCl3 (3.8 mL, 0.8 M), and then placed in a 105° C. oil bath. After being heated for 25 min, the reaction mixture was removed from the oil bath. After cooling for 5 min, the reaction mixture was concentrated under reduced pressure over 20 min, with the last 10 min at 55° C. and 11-13 mbar. Note, nitrogen was used to replace the vacuum. The flask containing the residue was charged with (R)-3-(Boc-amino)-piperidine (1.50 g, 2.5 equiv.) a stirbar, and N,N-dimethylforamide (7.5 mL, 0.4 M). After being stirred at room temperature overnight, the reaction solution was diluted with DMSO and purified by reverse phase chromatography (300 g C18 cartridge, CH3CN/H2O/0.1% HCO2H) to afford a brown solid that consisted of heterocycle 11 along with heterocycle 10. This material was used without additional purification. MS (M+1)+ m/z calcd for C25H29ClFN6O3=515.2. found m/z=515.0.
To a 0° C. suspension of the mixture of heterocycle 11 along with heterocycle 10 (0.69 g) in CH2Cl2 (15 mL) was added trifluoroacetic acid (4.3 mL). After 1 min, the cooling bath was removed. After being stirred at room temperature for 22.5 h, this solution was concentrated under reduced pressure. The resulting residue was dissolved in DMSO and purified by reverse phase chromatography (300 g C18 cartridge, CH3CN/H2O/0.1% HCO2H) to afford fractions containing Example 5. These fractions were concentrated, and then the residue was dissolved in H2O. This aq. solution was stirred with saturated aq. NaHCO3 for 20 min, and then extracted with CH2Cl2 (3×). The combined organic layers were dried over Na2SO4, filtered, concentrated under reduced pressure to afford Example 5 as a yellow solid. 1HNMR (CDCl3, 500 MHz) δ 7.70 (dd, 1H), 7.10 (ddd, 1H), 6.83 (dd, 1H), 6.35 (s, 1H), 5.42 (AB q, 2H), 3.67 (s, 3H), 3.45 (br d, 1H), 3.34 (m, 1H), 3.06 (br t, 1H), 2.98 (m, 1H), 2.86 (br t, 1H), 2.03 (m, 1H), 1.86 (m, 1H), 1.67 (m, 1H), 1.32 (m, 1H); MS (M+1)+ m/z calcd for C20H21ClFN6O=415.1. found m/z=415.0.




Example 6




A solution of compound 12 (3.00 g, 18.05 mmol.) in DMF (60 mL) was treated with K2CO3 (2.49 g, 18.05 mmol), 4-methoxybenzyl chloride (2.57 mL, 18.95 mmol) and heated at 60° C. for 1.5 hours. The reaction mixture was then poured over ice and neutralized with aqueous 2N HCl. The resulting precipitate was filtered and washed with H2O (2×75 mL). The precipitate was dried under vacuum to afford compound 13 as a white powder. 1H NMR (DMSO-d6, 400 MHz) δ 11.12 (s, 1H), 8.19 (s, 1H), 7.29-7.32 (m, 2H), 6.85-6.90 (m, 2H), 5.33 (s, 2H), 3.69 (s, 3H), 3.31 (s, 3H); MS (M+1)+ m/z calcd for C14H15N4O3=287.1. found m/z=287.1.
A solution of compound 13 (930 mg, 3.25 mmol) in DMF (20 mL) was treated with K2CO3 (449.1 mg, 3.25 mmol), 2-cyanobenzyl bromide (956.6 mg, 4.87 mmol) and heated at 70° C. for 2.0 hours. The reaction mixture was then poured over ice, and the resulting precipitate was filtered and washed with H2O (40 mL) and hexanes (40 mL). The precipitate was dried under vacuum to give compound 14 as a white powder. 1H NMR (DMSO-d6, 400 MHz) δ 8.27 (s, 1H), 7.78-7.83 (m, 1H), 7.40-7.59 (m, 2H), 7.21-7.31 (m, 3H), 6.83-6.91 (m, 2H), 5.38 (s, 2H), 5.19 (s, 2H), 3.69 (s, 3H), 3.36 (s, 3H); MS (M+1)+ m/z calcd for C22H20N5O3=402.2. found m/z=402.0.
A solution of compound 14 (400 mg, 0.99 mmol) in trifluoroacetic acid (12 mL) was treated with H2SO4 (5 drops), anisole (0.14 mL, 1.26 mmol) and heated to reflux for 24 hrs. The reaction mixture was concentrated and then dissolved in H2O (8 mL) and diisopropyl ether (30 mL). While being stirred, this mixture was treated with 20% aq. NaOH solution, dropwise, until a pH of 6 was achieved. The resulting precipitate was filtered and washed with H2O (30 mL) and diisopropyl ether (30 mL). The precipitate was dried under vacuum to give compound 15 as a pale yellow powder. 1H NMR (DMSO-d6, 400 MHz) δ 8.10 (s, 1H), 7.79-7.84 (m, 1H), 7.55-7.61 (m, 1H), 7.39-7.46 (m, 1H), 7.21-7.26 (m, 1H), 5.22 (s, 2H), 3.44 (s, 3H); MS (M+1)+ m/z calcd for C14H12N5O2=282.1. found m/z=282.2.
A solution of compound 15 (129.7 mg, 0.46 mmol) in sulfolane (2.0 mL.) was treated with POCl3 (1.7 mL), and then heated in a sealed tube at 150° C. After being heated for 1 hr, the reaction mixture was concentrated. The crude material was taken up in DMF (3.0 mL.) and treated with (R)-3-(Boc-amino)-piperidine (276.4 mg, 1.38 mmol) for 1 hr. at room temperature. The reaction mixture was poured over ice water, and while stirring, was neutralized with saturated aqueous NaHCO3 solution. The mixture was extracted with EtOAc (3×15 mL). The organic layers were dried over MgSO4, filtered, and concentrated. The crude material was purified by silica gel chromatography and eluted with (0%-5% Ammonia-MeOH/CH2C2) to give a yellow oil, which was then purified by reverse phase chromatography to afford the trifluoroacetic acid salt of compound 16 as a yellow solid. 1H NMR (CD3OD, 400 MHz) δ 8.43 (s, 1H), 7.48-7.74 (m, 4H), 5.38 (s, 2H), 4.28-4.31 (m, 1H) 3.57-3.63 (m, 2H), 3.44 (s, 3H), 2.99-3.10 (m, 2H), 1.43-1.85 (m, 4H), 1.38 (s, 9H); MS (M+1)+ m/z calcd for C24H30N7O3=464.2. found m/z=464.0.
A solution of compound 16 (30.0 mg, 0.065 mmol) in CH2Cl2 (0.8 mL) was cooled to 0° C., treated with trifluoroacetic acid (0.8 mL), and then warmed to room temperature. The reaction was concentrated in vacuo, and the resulting crude material was purified by reverse phase chromatography to give Example 6 as a trifluoroacetic acid salt. This salt was then partitioned between CH2Cl2 and saturated aq. NaHCO3. The CH2Cl2 layer was dried over MgSO4, filtered, concentrated, and dried under vacuum to give Example 6 as brown solid (3.5 mg, 12%). 1H NMR (CDCl3, 400 MHz) δ 7.87 (s, 1H), 7.48-7.74 (m, 4H), 5.38 (s, 2H), 3.81 (m, 1H), 3.64 (s 3H), 3.25-3.40 (m, 2H), 2.99-3.10 (m, 2H), 1.43-1.85 (m, 4H)); MS (M+1)+ m/z calcd for C19H22N7O=364.2. found m/z=364.2.




Example 7




Note, this reaction was performed in a glovebox. A 50 mM solution of sulfuric acid (28.6 mL cone. H2SO4 in 10 mL of N,N-dimethylacetamide) was agitated uncovered for 5 minutes. A separate vial was charged with RuPhos (252 mg, 0.54 mmol) and N,N-dimethylacetamide (8.1 mL). A separate vial was charged with Pd(OAc)2 (60.6 mg, 0.27 mmol) and the previously prepared sulfuric acid/DMA solution (5.5 mL). The Pd(OAc)2 solution was then charged to the vial that contained the RuPhos solution. This catalyst solution was then heated at 80° C. for 15 minutes. In a separate vial, compound 9 (390 mg, 0.90 mmol) was dissolved in the previously prepared sulfuric acid/DMA solution (1.8 mL), and then charged with previously prepared catalyst solution (4.5 mL). A separate vial was charged with zinc cyanide (75 mg, 0.63 mmol), zinc dust (12 mg, 0.18 mmol), and N,N-dimethylacetamide (1.2 mL). The solution containing compound 9 was then charged to the vial containing the zinc slurry and heated to 125° C. for 1.5 hours. The reaction mixture was then charged with an additional amount of the previously made catalyst solution (2.25 mL), and heated at 125° C. for an additional 16.5 hours. The reaction mixture was then diluted with water and brine, extracted with tert-butyl methyl ether, dried over Na2SO4, and concentrated. The crude reaction mixture was purified via C18 column using acetonitrile/water/0.1% formic acid. The resulting material containing compound 17 was used without further purification. 1HNMR (DMSO-d6, 500 MHz) δ 13.20 (br s, 1H), δ 7.95 (m, 1H), δ 7.33 (m, 2H), δ 7.10 (m, 1H), δ 5.19 (s, 2H), δ 3.43 (s, 31H); MS (M+1)+ m/z calcd for C16H1FN5O2+=324.1. found m/z=324.
Example 7 was synthesized from compound 17 by a method similar to that outlined for the conversion of compound 10 to Example 5. Data for Example 7: 1HNMR (CDCl3-d6, 500 MHz) δ 7.70 (m, 1H), δ 7.11 (m, 21), δ 6.99 (m, 1H), δ 5.38 (m, 2H), δ 3.64 (s, 3H), δ 3.57 (m, 2H), δ 3.26 (m, 1H), δ 3.10 (m, 1H), δ 3.02 (m, 1H), δ 2.08 (m, 1H), δ 1.95 (m, 1H), δ 1.70-1.40 (m, 4H that are buried by H2O); MS (M+1)+ m/z calcd for C21H21FN7O+=406.2. found m/z=406.2.




Example 8




To a round-bottomed flask under nitrogen that contained compound 18 (15.0 g, 77.86 mmol) and sodium azide (20.24 g, 311.46 mmol) was added anhydrous DMF (156 mL). The reaction was heated at 80° C. for 16 hours. The reaction was cooled to room temperature, diluted with ethyl acetate/hexanes (70:30, 1.7 L), washed with brine, dried over sodium sulfate, and concentrated to afford 13.05 g of compound 19 as an orange solid. This material was used without further purification. 1HNMR (CDCl3, 500 MHz) δ 8.11 (m, 1H), δ 8.05 (m, 1H), δ 7.89 (m, 1H), δ 7.64 (m, 1H), δ 4.67 (s, 2H), δ 2.97 (s, 3H); MS (M+1)+ m/z calcd for C10H10N5+=200.1. found m/z=200.2.
Compound 19 (13.05 g, 65.51 mmol), PPh3 (polymer bound,  ̃3 mmol/g loading (28.4 g, 85.16 mmol)), water (33 mL), and THF (131 mL) were placed in a round-bottomed flask and heated to 70° C. for 2.5 hours. The reaction mixture was filtered, washed with CH2Cl2, dried over sodium sulfate, and concentrated. The crude material was purified silica gel with CH2Cl2/MeOH/NH4OH to afford compound 20 (7.93 g at 90% purity, 53% over 2 steps). 1HNMR (CDCl3, 400 MHz) 8.09 (m, 1H), δ 8.06 (m, 1H), δ 7.86 (m, 1H), δ 7.59 (m, 1H), δ 4.22 (s, 2H), δ 2.94 (s, 3H), δ 1.94 (br s, 2H); MS (M+1)+ m/z calcd for C10H12N3+=174.1. found m/z=174.2.
To a mixture of compound 20 (7.74 g, 44.68 mmol) in aq. sulfuric acid (0.5 M, 45 mL) at 85° C. was added potassium cyanate (7.24 g, 22.34 mmol) portion-wise. The reaction was heated at 85° C. for 2 hours then cooled to room temperature. The reaction was then cooled in an ice-bath, filtered and washed with cold water to afford compound 21 (8.38 g, 87%) as a yellow solid. 1HNMR (DMSO-d6, 400 MHz) δ 8.27 (m, 1H), δ 7.96 (m, 2H), δ 7.70 (m, 1H), δ 6.54 (t, 1H), δ 5.74 (s, 2H), δ 4.99 (d, 2H), δ 2.91 (s, 3H); MS (M+1)+ m/z calcd for C11H13N4O+=217.1. found m/z=217.2.
To a round-bottomed flask that contained compound 21 (8.38 g, 38.75 mmol), and cyano acetic acid (3.95 g, 46.5 mmol) was added acetic anhydride (0.75 M, 52 mL). The reaction was heated to 70° C. for 1.5 hours and was then stirred at room temperature overnight. The reaction mixture was diluted with Et2O and filtered to afford compound 22 (10.1 g, 92%) as a red solid. 1HNMR (DMSO-d6, 400 MHz) δ 10.74 (s, 1H), δ 8.96 (br s, 1H), δ 8.29 (m, 1H), δ 7.98 (m, 2H), δ 7.72 (s, 1H), δ 4.69 (d, 2H), δ 3.98 (s, 2H), δ 2.92 (s, 3H); MS (M+1)+ m/z calcd for C14H14N5O2+=284.1. found m/z=284.2.
To a mixture of compound 22 (9.62 g, 33.96 mmol) and isopropyl alcohol (0.11 M, 308 mL), and under nitrogen was added K2CO3 (4.69 g, 33.96 mmol). The reaction vessel was placed in a preheated oil-bath at 80° C. and heated at 80° C. for 3 hours. Additional K2CO3 (0.5 equiv.) was added after 3 hours, and then the reaction stirred at 80° C. for 16 hours. The reaction was cooled to room temperature and concentrated in vacuo until there was approximately 100 mL of isopropyl alcohol remaining. The resulting mixture was diluted with water, neutralized with aq. HCl (1 M), cooled in an ice-bath, and filtered to afford compound 23 (8.185 g, 85%) as a brown solid. 1HNMR (DMSO-d6, 500 MHz) δ 10.39 (s, 1H), δ 8.27 (m, 1H), δ 7.95 (m, 1H), δ 7.87 (m, 1H), δ 7.70 (m, 1H), δ 6.73 (s, 2H), δ 5.73 (s, 2H), δ 4.98 (s, 1H), δ 2.91 (s, 3H); MS (M+1)+ m/z calcd for C14H14N5O2+=284.1. found m/z=284.2.
Example 8 was synthesized from compound 23 by a method similar to that outlined for Example 1. Data for Example 8: 1HNMR (CDCl3, 500 MHz) δ 8.02 (m, 1H), δ 7.87 (m, 1H), δ 7.78 (m, 1H), δ 7.68 (m, 1H), δ 7.53 (m, 1H), δ 7.22 (d, 1H), δ 7.04 (m, 2H), δ 6.54 (d, 1H), δ 5.85 (s, 2H), δ 5.55 (s, 2H), δ 3.52 (m, 1H) δ 3.38 (m, 1H), δ 3.11 (m, 1H), δ 2.97 (m, 2H), δ 2.88 (s, 3H), δ 2.04 (m, 1H), δ 1.85 (m, 1H), δ 1.69 (m, 1H), δ 1.50-1.47 (br s, 3H buried by H2O); MS (M+1)+ m/z calcd for C29H28FN8O+=523.2. found m/z=523.2.
Assay
DPP4 Enzyme Inhibition Assay (IC50 Measurement)
DPP4 activity was measured using a continuous fluorometric assay. The substrate, Gly-Pro-AMC, was cleaved by DPP4 to release the fluorescent AMC group. The reaction was monitored at the excitation wavelength of 360 nm and emission wavelength of 460 nm in a black 384-well plate using a PHERAstar Plus plate reader (BMG Labtech., Inc.) set at 37° C. The 30 μl assay solution contained 20 μM recombinant human DPP4 and 50 μM Gly-Pro-AMC substrate in assay buffer (100 mM HEPES, 100 mM NaCl, 0.1 mg/ml BSA, pH 7.5). The reaction was linear for at least 30 min (initial velocity) after addition of the substrate (no inhibitor control). All materials and reagents were pre-incubated at 37° C. prior to start of the experiment. Test compounds were serially diluted (3-fold) in 100% DMSO to avoid solubility issues; working solutions in 3% DMSO were prepared using assay buffer. 101 each of enzyme and compound solutions were mixed and pre-incubated at 37° C. for 30 minutes. 101 substrate (pre-incubated at 37° C.) was added and the plate was immediately loaded and shaken (5 sec.) prior to signal detection. The final concentration of DMSO was 1%. The initial velocity (slope of the reaction curve) was calculated using linear regression fit using the MARS software (BMG Labtech., Inc.). IC50 calculations are done by fitting the data to a non-linear (inhibitor) dose-response equation using Prism software.














Example No.
DPP-IV IC50 (nM)



















Example 1
5.7



Example 2
34



Example 3
1343



Example 4
1590



Example 5
5.6



Example 6
106



Example 7
14



Example 8
104










Example of a Pharmaceutical Formulation

As a specific embodiment of an oral pharmaceutical composition, a 100 mg potency tablet is composed of 100 mg of any one of the Examples, 268 mg microcrystalline cellulose, 20 mg of croscarmellose sodium, and 4 mg of magnesium stearate. The active, microcrystalline cellulose, and croscarmellose are blended first. The mixture is then lubricated by magnesium stearate and pressed into tablets.
While the invention has been described and illustrated with reference to certain particular embodiments thereof, those skilled in the art will appreciate that various adaptations, changes, modifications, substitutions, deletions, or additions of procedures and protocols may be made without departing from the spirit and scope of the invention. For example, effective dosages other than the particular dosages as set forth herein above may be applicable as a consequence of variations in responsiveness of the mammal being treated for any of the indications with the compounds of the invention indicated above. The specific pharmacological responses observed may vary according to and depending upon the particular active compounds selected or whether there are present pharmaceutical carriers, as well as the type of formulation and mode of administration employed, and such expected variations or differences in the results are contemplated in accordance with the objects and practices of the present invention. It is intended, therefore, that the invention be defined by the scope of the claims which follow and that such claims be interpreted as broadly as is reasonable.

## Claims

1. A compound of structural formula I:




or a pharmaceutically acceptable salt thereof; wherein X1 and X2 are independently selected from the group consisting of —N— and —CR5—;
R1 is selected from the group consisting of hydrogen, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, aryl, heterocycle, aroyl, heteroaroyl and C3-C10cycloalkyl; wherein the C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, aryl, heterocycle, aroyl, heteroaroyl and C3-C10cycloalkyl are unsubstituted or substituted with 1-3 substituents from R5;
R2 is selected from the group consisting of C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, benzyl, heterocycle and C1-C6alkylheterocycle; wherein the C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, benzyl, heterocycle and C1-C6alkylheterocycle are unsubstituted or substituted with 1-3 substituents each independently selected from R3, R4 and R5;
R3 is selected from the group consisting of hydrogen, C1-C6alkyl and aryl, wherein the C1-C6alkyl and aryl are unsubstituted or substituted with 1-3 substituents selected from R5;
R4 is selected from the group consisting of hydrogen and C1-C6alkyl;
R5 is selected from the group consisting of hydrogen, halogen, C1-C6alkyl, halogen-substitutedC1-C6alkyl, —OH, C1-C6alkylOH, halogen-substitutedC1-C6alkylOH, —OC1-C6alkyl, —Ohalogen-substitutedC1-C6alkyl, —COOH, —COOC1-C6alkyl, —C1-C6alkylCOOC1-C6alkyl, —C1-C6alkylCOOH, —CN, C1-C6alkylCN, NHC1-C6alkyl, N(C1-C6alkyl)2, C1-C6alkylCONH2, —CONH2, —CONHC1-C6alkyl, —NHCOC1-C6alkyl, —CON(C1-C6alkyl)2, —NHSO2C1-C6alkyl, SO2aryl, —SO2C1-C6alkyl, C1-C6alkylSO2C1-C6alkyl, aryl, —NHCOaryl, and —NHCOheterocycle; and
n is 0-4.

2. The compound of claim 1 or pharmaceutically acceptable salt thereof wherein X1 is —N— and X2 is —CR5—.

3. The compound of claim 1 or pharmaceutically acceptable salt thereof wherein X1 and X2 are —N—.

4. The compound of claim 1 or pharmaceutically acceptable salt thereof wherein R1 is heterocycle.

5. The compound of claim 1 or pharmaceutically acceptable salt thereof wherein R1 is selected from the group consisting of:

6. The compound of claim 1 or pharmaceutically acceptable salt thereof wherein R1 is hydrogen.

7. The compound of claim 1 or pharmaceutically acceptable salt thereof wherein R1 is C1-C6alkyl.

8. The compound of claim 1 or pharmaceutically acceptable salt thereof wherein n is 1.

9. The compound of claim 1 or pharmaceutically acceptable salt thereof wherein R2 is selected from the group consisting of:

10. The compound of claim 1 or pharmaceutically acceptable salt thereof wherein R2 is selected from the group consisting of C2-C6alkenyl, C2-C6alkynyl and benzyl, wherein C2-C6alkenyl, C2-C6alkynyl and benzyl are unsubstituted or substituted with 1-3 substituents selected from R5.

11. The compound of claim 1 or pharmaceutically acceptable salt thereof wherein R2 is selected from the group consisting of 2-butynyl, 2,5-difluorobenzyl, 2,4,5-trifluorobenzyl, 2-cyanobenzyl, 2-cyano-5-fluorobenzyl, 2-cyano-4,5-difluorobenzyl, 2,4-dichlorobenzyl 2,5-dichlorobenzyl, and 2-bromo-5-fluorobenzyl.

12. The compound of claim 1 or pharmaceutically acceptable salt thereof wherein R5 is selected from the group consisting of hydrogen, halogen, and —CN.

13. A compound of structural formula Ia:




or a pharmaceutically acceptable salts thereof; wherein X1, X2, n, R1, R2 and R5 are as described in claim 1.

14. A compound or pharmaceutically acceptable salt, selected from the group consisting of:

15. A pharmaceutical composition which comprises a compound of claim 1 and a pharmaceutically acceptable carrier.

16. The pharmaceutical composition of claim 15 additionally comprising a second agent selected from the group consisting of metformin, pioglitazone, rosiglitazone, a sulfonylurea, and an HMG-CoA reductase inhibitor.

17. A method of treating a condition selected from the group consisting of insulin resistance, hyperglycemia, and Type 2 diabetes by administering a therapeutically effective amount of a compounds of claim 1, or a pharmaceutically acceptable salt thereof to a patient in need thereof.